https://trial.medpath.com/news/beckley-psytech-announces-positive-results-for-ele-101-in-depression-trial 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/beckley-psytech-announces-positive-results-for-ele-101-in-depression-trial 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/heartsciences-reports-second-quarter-fiscal-2025-financial-results-and-business-update 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/heartsciences-reports-second-quarter-fiscal-2025-financial-results-and-business-update 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/success-with-adjuvant-ribociclib-leads-to-fda-approval-in 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/success-with-adjuvant-ribociclib-leads-to-fda-approval-in 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-study-finds-psychedelic-drug-can-help-ease-depression-among-healthcare-workers 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-study-finds-psychedelic-drug-can-help-ease-depression-among-healthcare-workers 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/top-5-most-read-all-aml-articles-in-2024 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-5-most-read-all-aml-articles-in-2024 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eo-3021-demonstrates-effectiveness-in-cldn18-2-expressing-cancer-models 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eo-3021-demonstrates-effectiveness-in-cldn18-2-expressing-cancer-models 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/trial-investigating-v940-and-pembrolizumab-for-squamous-cell-skin-cancer-treatment 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trial-investigating-v940-and-pembrolizumab-for-squamous-cell-skin-cancer-treatment 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/percheron-therapeutics-halts-trading-ahead-of-trial-results 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/percheron-therapeutics-halts-trading-ahead-of-trial-results 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/invios-to-showcase-oncology-pipeline-progress-at-jp-morgan-week-2025 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/invios-to-showcase-oncology-pipeline-progress-at-jp-morgan-week-2025 2024-12-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/here-are-5-asx-biotechs-expecting-clinical-trial-results-in-the-next-few-months 2024-12-15T23:52:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/here-are-5-asx-biotechs-expecting-clinical-trial-results-in-the-next-few-months 2024-12-15T23:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/tiny-robots-thinner-than-a-human-hair-could-help-fight-cancer-tumours-reveals-study 2024-12-15T23:51:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tiny-robots-thinner-than-a-human-hair-could-help-fight-cancer-tumours-reveals-study 2024-12-15T23:51:00+00:00 weekly 0.7 https://trial.medpath.com/news/mixed-signals-from-trials-of-perioperative-neoadjuvant-immunotherapy-for-early-tnbc 2024-12-15T22:46:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mixed-signals-from-trials-of-perioperative-neoadjuvant-immunotherapy-for-early-tnbc 2024-12-15T22:46:18+00:00 weekly 0.7 https://trial.medpath.com/news/protagonist-therapeutics-swot-analysis-stock-poised-for-growth-amid-clinical-trials 2024-12-15T21:30:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protagonist-therapeutics-swot-analysis-stock-poised-for-growth-amid-clinical-trials 2024-12-15T21:30:43+00:00 weekly 0.7 https://trial.medpath.com/news/professor-kim-gun-ho-receives-fda-approval-for-ocucool-eye-anesthesia-technology 2024-12-15T21:18:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/professor-kim-gun-ho-receives-fda-approval-for-ocucool-eye-anesthesia-technology 2024-12-15T21:18:18+00:00 weekly 0.7 https://trial.medpath.com/news/advancing-epilepsy-treatment-with-novel-approaches-and-predictive-technologies-neurologylive 2024-12-15T21:16:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advancing-epilepsy-treatment-with-novel-approaches-and-predictive-technologies-neurologylive 2024-12-15T21:16:25+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-and-neomorph-forge-1-64-billion-molecular-glue-degrader-partnership-for-oncology-and-immunology 2024-12-15T21:01:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-and-neomorph-forge-1-64-billion-molecular-glue-degrader-partnership-for-oncology-and-immunology 2024-12-15T21:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/cwr-expands-clinical-trials-to-tackle-high-disease-burden-in-nigeria-others 2024-12-15T20:49:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cwr-expands-clinical-trials-to-tackle-high-disease-burden-in-nigeria-others 2024-12-15T20:49:25+00:00 weekly 0.7 https://trial.medpath.com/news/2nd-phase-transgenic-silkworm-trials-focus-on-virus-resistance-times-of-india 2024-12-15T19:13:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2nd-phase-transgenic-silkworm-trials-focus-on-virus-resistance-times-of-india 2024-12-15T19:13:57+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-and-2seventy-bio-s-car-t-ide-cel-effects-responses-in-cns-involved 2024-12-15T17:19:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-squibb-and-2seventy-bio-s-car-t-ide-cel-effects-responses-in-cns-involved 2024-12-15T17:19:11+00:00 weekly 0.7 https://trial.medpath.com/news/lipigon-pharmaceuticals-appoints-new-ceo-marketscreener 2024-12-15T17:01:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lipigon-pharmaceuticals-appoints-new-ceo-marketscreener 2024-12-15T17:01:42+00:00 weekly 0.7 https://trial.medpath.com/news/intas-pharmaceutical-gets-cdsco-panel-nod-to-study-aflibercept-solution-for-injection-40 2024-12-15T16:36:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intas-pharmaceutical-gets-cdsco-panel-nod-to-study-aflibercept-solution-for-injection-40 2024-12-15T16:36:34+00:00 weekly 0.7 https://trial.medpath.com/news/evaluating-belzutifan-for-clear-cell-renal-cell-carcinoma-treatment-targeted-oncology 2024-12-15T16:22:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluating-belzutifan-for-clear-cell-renal-cell-carcinoma-treatment-targeted-oncology 2024-12-15T16:22:28+00:00 weekly 0.7 https://trial.medpath.com/news/stockwatch-q32-shares-crater-85-as-investors-analysts-sour-on-trial-results 2024-12-15T16:07:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stockwatch-q32-shares-crater-85-as-investors-analysts-sour-on-trial-results 2024-12-15T16:07:17+00:00 weekly 0.7 https://trial.medpath.com/news/outpatient-lymphodepletion-prior-to-brexu-cel-is-safe-effective-in-b-all-mcl 2024-12-15T15:55:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/outpatient-lymphodepletion-prior-to-brexu-cel-is-safe-effective-in-b-all-mcl 2024-12-15T15:55:11+00:00 weekly 0.7 https://trial.medpath.com/news/commentary-kudos-criticism-mark-california-stem-cell-agency-as-it-turns-20-stocktonia 2024-12-15T15:51:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/commentary-kudos-criticism-mark-california-stem-cell-agency-as-it-turns-20-stocktonia 2024-12-15T15:51:14+00:00 weekly 0.7 https://trial.medpath.com/news/promising-combination-therapy-could-improve-liver-cancer-outcomes-news-medical 2024-12-15T14:49:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promising-combination-therapy-could-improve-liver-cancer-outcomes-news-medical 2024-12-15T14:49:20+00:00 weekly 0.7 https://trial.medpath.com/news/is-pfizer-a-millionaire-maker-yahoo-finance 2024-12-15T14:45:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/is-pfizer-a-millionaire-maker-yahoo-finance 2024-12-15T14:45:53+00:00 weekly 0.7 https://trial.medpath.com/news/weight-loss-linked-to-lower-inflammatory-markers-in-women-with-breast-cancer-healio 2024-12-15T14:39:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weight-loss-linked-to-lower-inflammatory-markers-in-women-with-breast-cancer-healio 2024-12-15T14:39:41+00:00 weekly 0.7 https://trial.medpath.com/news/francoise-bernaudin-md-on-allosct-superiority-over-soc-for-sickle-cell-anemia 2024-12-15T14:23:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/francoise-bernaudin-md-on-allosct-superiority-over-soc-for-sickle-cell-anemia 2024-12-15T14:23:57+00:00 weekly 0.7 https://trial.medpath.com/news/mind-medicine-s-swot-analysis-stock-poised-for-growth-in-anxiety-treatment-investing-com 2024-12-15T14:12:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mind-medicine-s-swot-analysis-stock-poised-for-growth-in-anxiety-treatment-investing-com 2024-12-15T14:12:35+00:00 weekly 0.7 https://trial.medpath.com/news/investigational-hepatitis-d-therapy-well-tolerated-safe-for-chronic-disease-at-week-48 2024-12-15T13:26:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/investigational-hepatitis-d-therapy-well-tolerated-safe-for-chronic-disease-at-week-48 2024-12-15T13:26:38+00:00 weekly 0.7 https://trial.medpath.com/news/gan-lee-pharmaceutical-rose-0-68-this-week-and-the-biological-products-sector-fell-1-58 2024-12-15T12:35:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gan-lee-pharmaceutical-rose-0-68-this-week-and-the-biological-products-sector-fell-1-58 2024-12-15T12:35:48+00:00 weekly 0.7 https://trial.medpath.com/news/2-weight-loss-stocks-that-are-screaming-buys-in-december 2024-12-15T12:17:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2-weight-loss-stocks-that-are-screaming-buys-in-december 2024-12-15T12:17:53+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-s-melanoma-treatment-nears-key-milestones 2024-12-15T11:09:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/replimune-s-melanoma-treatment-nears-key-milestones 2024-12-15T11:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/artiva-biotherapeutics-s-swot-analysis-nk-cell-therapy-stock-poised-for-autoimmune-breakthrough 2024-12-15T09:51:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/artiva-biotherapeutics-s-swot-analysis-nk-cell-therapy-stock-poised-for-autoimmune-breakthrough 2024-12-15T09:51:26+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-opportunity-for-erectile-dysfunction-treatment 2024-12-15T09:21:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-opportunity-for-erectile-dysfunction-treatment 2024-12-15T09:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-gene-therapy-for-haemophilia-a-at-christian-medical-college-vellore 2024-12-15T09:06:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-gene-therapy-for-haemophilia-a-at-christian-medical-college-vellore 2024-12-15T09:06:00+00:00 weekly 0.7 https://trial.medpath.com/news/yifang-biopharma-on-december-4-it-was-surveyed-by-institutions-including-well-known 2024-12-15T05:53:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/yifang-biopharma-on-december-4-it-was-surveyed-by-institutions-including-well-known 2024-12-15T05:53:32+00:00 weekly 0.7 https://trial.medpath.com/news/ponatinib-related-toxicity-management-in-all-cml-improves-over-time-cancer-network 2024-12-15T05:13:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ponatinib-related-toxicity-management-in-all-cml-improves-over-time-cancer-network 2024-12-15T05:13:27+00:00 weekly 0.7 https://trial.medpath.com/news/fate-therapeutics-advances-in-autoimmune-disease-treatment-with-promising-cell-therapy-programs 2024-12-15T04:38:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fate-therapeutics-advances-in-autoimmune-disease-treatment-with-promising-cell-therapy-programs 2024-12-15T04:38:00+00:00 weekly 0.7 https://trial.medpath.com/news/behind-the-leap-012-trial-of-lenvatinib-pembrolizumab-and-tace-in-hcc 2024-12-15T04:12:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/behind-the-leap-012-trial-of-lenvatinib-pembrolizumab-and-tace-in-hcc 2024-12-15T04:12:13+00:00 weekly 0.7 https://trial.medpath.com/news/inovio-s-swot-analysis-biotech-stock-faces-manufacturing-hurdles-amid-pipeline-progress 2024-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inovio-s-swot-analysis-biotech-stock-faces-manufacturing-hurdles-amid-pipeline-progress 2024-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/key-highlights-from-the-american-society-of-hematology-meeting-and-regulatory-updates 2024-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/key-highlights-from-the-american-society-of-hematology-meeting-and-regulatory-updates 2024-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/oppenheimer-predicts-significant-growth-for-sagimet-and-y-mabs-therapeutics 2024-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oppenheimer-predicts-significant-growth-for-sagimet-and-y-mabs-therapeutics 2024-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gdf-15-inhibitors-show-promise-against-hard-to-treat-tumors-in-clinical-trial 2024-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gdf-15-inhibitors-show-promise-against-hard-to-treat-tumors-in-clinical-trial 2024-12-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/adjuvant-anthracycline-plus-taxane-based-chemotherapy-regimen-improves-survival-in-high 2024-12-14T23:15:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adjuvant-anthracycline-plus-taxane-based-chemotherapy-regimen-improves-survival-in-high 2024-12-14T23:15:18+00:00 weekly 0.7 https://trial.medpath.com/news/psilocybin-industry-will-focus-on-fine-tuning-first-in-the-nation-program-in-2025-opb 2024-12-14T22:48:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psilocybin-industry-will-focus-on-fine-tuning-first-in-the-nation-program-in-2025-opb 2024-12-14T22:48:18+00:00 weekly 0.7 https://trial.medpath.com/news/russia-announces-free-personalized-cancer-vaccine-the-pinnacle-gazette 2024-12-14T21:12:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/russia-announces-free-personalized-cancer-vaccine-the-pinnacle-gazette 2024-12-14T21:12:25+00:00 weekly 0.7 https://trial.medpath.com/news/aaron-nagial-md-phd-gives-interview-on-the-impact-of-retinal-gene-therapy-procedure 2024-12-14T20:46:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aaron-nagial-md-phd-gives-interview-on-the-impact-of-retinal-gene-therapy-procedure 2024-12-14T20:46:43+00:00 weekly 0.7 https://trial.medpath.com/news/a-low-omega-6-omega-3-rich-diet-and-fish-oil-may-slow-prostate-cancer-growth-ucla-study-finds 2024-12-14T20:06:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-low-omega-6-omega-3-rich-diet-and-fish-oil-may-slow-prostate-cancer-growth-ucla-study-finds 2024-12-14T20:06:22+00:00 weekly 0.7 https://trial.medpath.com/news/jennifer-b-green-md-implementation-of-evidence-based-therapies-for-t2d-hcplive 2024-12-14T19:41:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jennifer-b-green-md-implementation-of-evidence-based-therapies-for-t2d-hcplive 2024-12-14T19:41:46+00:00 weekly 0.7 https://trial.medpath.com/news/sensome-data-supports-clot-sensing-guidewire-massdevice 2024-12-14T18:19:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sensome-data-supports-clot-sensing-guidewire-massdevice 2024-12-14T18:19:37+00:00 weekly 0.7 https://trial.medpath.com/news/japanese-researchers-test-pioneering-drug-to-regrow-teeth-medical-xpress 2024-12-14T18:09:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/japanese-researchers-test-pioneering-drug-to-regrow-teeth-medical-xpress 2024-12-14T18:09:51+00:00 weekly 0.7 https://trial.medpath.com/news/kura-oncology-s-swot-analysis-ziftomenib-s-promise-drives-stock-outlook-investing-com 2024-12-14T17:23:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kura-oncology-s-swot-analysis-ziftomenib-s-promise-drives-stock-outlook-investing-com 2024-12-14T17:23:04+00:00 weekly 0.7 https://trial.medpath.com/news/letter-to-the-fda-commissioner-requesting-an-investigation-of-the-conduct-of-alzheimer-s 2024-12-14T15:39:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/letter-to-the-fda-commissioner-requesting-an-investigation-of-the-conduct-of-alzheimer-s 2024-12-14T15:39:19+00:00 weekly 0.7 https://trial.medpath.com/news/soxrc-regimen-improves-responses-versus-chemo-alone-in-advanced-gastric-cancers 2024-12-14T15:04:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/soxrc-regimen-improves-responses-versus-chemo-alone-in-advanced-gastric-cancers 2024-12-14T15:04:28+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-s-ozempic-reportedly-linked-to-vision-loss-in-new-study-yahoo-finance 2024-12-14T14:42:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-nordisk-s-ozempic-reportedly-linked-to-vision-loss-in-new-study-yahoo-finance 2024-12-14T14:42:42+00:00 weekly 0.7 https://trial.medpath.com/news/curateq-biologics-receives-positive-opinion-for-biosimilar-zefylti-indian-pharma-post 2024-12-14T14:07:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/curateq-biologics-receives-positive-opinion-for-biosimilar-zefylti-indian-pharma-post 2024-12-14T14:07:58+00:00 weekly 0.7 https://trial.medpath.com/news/lower-aldosterone-thresholds-linked-to-increased-hypertension-risk-in-landmark-breakthrough-study 2024-12-14T14:00:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lower-aldosterone-thresholds-linked-to-increased-hypertension-risk-in-landmark-breakthrough-study 2024-12-14T14:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/what-happened-in-optometry-this-week-december-9 2024-12-14T12:54:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-happened-in-optometry-this-week-december-9 2024-12-14T12:54:07+00:00 weekly 0.7 https://trial.medpath.com/news/phase-i-gynecological-cancer-data-sink-repare-shares-bioworld 2024-12-14T12:33:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-i-gynecological-cancer-data-sink-repare-shares-bioworld 2024-12-14T12:33:02+00:00 weekly 0.7 https://trial.medpath.com/news/new-research-highlights-potential-of-diabetes-medications-in-reducing-dementia-risk 2024-12-14T12:30:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-research-highlights-potential-of-diabetes-medications-in-reducing-dementia-risk 2024-12-14T12:30:54+00:00 weekly 0.7 https://trial.medpath.com/news/the-biggest-medical-breakthroughs-of-2024-gizmodo 2024-12-14T12:08:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-biggest-medical-breakthroughs-of-2024-gizmodo 2024-12-14T12:08:09+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-says-andexxa-will-not-convert-to-full-approval-quietly-reveals-complete-response 2024-12-14T11:57:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-says-andexxa-will-not-convert-to-full-approval-quietly-reveals-complete-response 2024-12-14T11:57:16+00:00 weekly 0.7 https://trial.medpath.com/news/biontech-se-and-its-partner-oncoc4-inc-continue-enrollment-in-phase-3-trial-for-bnt316 2024-12-14T11:39:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biontech-se-and-its-partner-oncoc4-inc-continue-enrollment-in-phase-3-trial-for-bnt316 2024-12-14T11:39:10+00:00 weekly 0.7 https://trial.medpath.com/news/enrollment-hits-75-for-phase-2b-clinical-trial-of-haduvio-for-ipf-pulmonary-fibrosis-news 2024-12-14T11:28:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enrollment-hits-75-for-phase-2b-clinical-trial-of-haduvio-for-ipf-pulmonary-fibrosis-news 2024-12-14T11:28:17+00:00 weekly 0.7 https://trial.medpath.com/news/rising-obesity-in-type-1-diabetes-patients-signals-need-for-new-cardiovascular-treatment-approaches 2024-12-14T10:30:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rising-obesity-in-type-1-diabetes-patients-signals-need-for-new-cardiovascular-treatment-approaches 2024-12-14T10:30:17+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-data-and-ai-help-improve-ild-management-in-her2-breast-cancer 2024-12-14T09:03:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-data-and-ai-help-improve-ild-management-in-her2-breast-cancer 2024-12-14T09:03:30+00:00 weekly 0.7 https://trial.medpath.com/news/new-hpv-self-test-approach-could-enhance-cervical-cancer-screening-news-medical 2024-12-14T08:42:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-hpv-self-test-approach-could-enhance-cervical-cancer-screening-news-medical 2024-12-14T08:42:29+00:00 weekly 0.7 https://trial.medpath.com/news/cgtlive-r-s-weekly-rewind-december-13-2024 2024-12-14T08:12:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cgtlive-r-s-weekly-rewind-december-13-2024 2024-12-14T08:12:28+00:00 weekly 0.7 https://trial.medpath.com/news/the-effect-of-acupuncture-intervention-on-chronic-musculoskeletal-pain-jpr-dove-medical-press 2024-12-14T07:17:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-effect-of-acupuncture-intervention-on-chronic-musculoskeletal-pain-jpr-dove-medical-press 2024-12-14T07:17:52+00:00 weekly 0.7 https://trial.medpath.com/news/cg-oncology-positive-phase-3-outcome-could-lead-to-bla-of-cretostimogene 2024-12-14T07:14:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cg-oncology-positive-phase-3-outcome-could-lead-to-bla-of-cretostimogene 2024-12-14T07:14:46+00:00 weekly 0.7 https://trial.medpath.com/news/ai-powered-mammography-analysis-shows-promise-for-long-term-breast-cancer-prevention 2024-12-14T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-powered-mammography-analysis-shows-promise-for-long-term-breast-cancer-prevention 2024-12-14T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/coa-2024-value-based-care-challenges-and-pbm-reform-take-center-stage-in-oncology 2024-12-14T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/coa-2024-value-based-care-challenges-and-pbm-reform-take-center-stage-in-oncology 2024-12-14T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/miller-school-spinoff-uses-rna-to-tackle-deadly-disease-inventum 2024-12-14T03:03:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/miller-school-spinoff-uses-rna-to-tackle-deadly-disease-inventum 2024-12-14T03:03:54+00:00 weekly 0.7 https://trial.medpath.com/news/emerging-research-leveraging-technology-in-phase-i-clinical-trials-massbio 2024-12-14T02:29:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emerging-research-leveraging-technology-in-phase-i-clinical-trials-massbio 2024-12-14T02:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/study-confirms-semaglutide-link-to-increased-but-low-risk-of-naion-markets-insider 2024-12-14T02:22:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-confirms-semaglutide-link-to-increased-but-low-risk-of-naion-markets-insider 2024-12-14T02:22:08+00:00 weekly 0.7 https://trial.medpath.com/news/edesa-biotech-reports-fiscal-year-2024-results-stock-titan 2024-12-14T01:42:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/edesa-biotech-reports-fiscal-year-2024-results-stock-titan 2024-12-14T01:42:45+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-pipelines-shrink-as-incyte-iteos-cut-candidates-following-disappointing-data 2024-12-14T01:41:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-pipelines-shrink-as-incyte-iteos-cut-candidates-following-disappointing-data 2024-12-14T01:41:33+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-co-brass-face-investor-suit-over-drug-trial-probe-law360 2024-12-14T01:00:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharma-co-brass-face-investor-suit-over-drug-trial-probe-law360 2024-12-14T01:00:43+00:00 weekly 0.7 https://trial.medpath.com/news/new-leash-on-life-cape-coral-shelter-dog-beats-cancer-with-drug-being-tested-for-humans 2024-12-14T00:07:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-leash-on-life-cape-coral-shelter-dog-beats-cancer-with-drug-being-tested-for-humans 2024-12-14T00:07:57+00:00 weekly 0.7 https://trial.medpath.com/news/cosibelimab-approved-by-fda-for-metastatic-locally-advanced-cutaneous-squamous-cell 2024-12-14T00:02:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cosibelimab-approved-by-fda-for-metastatic-locally-advanced-cutaneous-squamous-cell 2024-12-14T00:02:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-suspends-valneva-s-chikungunya-vaccine-license-following-severe-adverse-events-in-elderly-patients 2024-12-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-suspends-valneva-s-chikungunya-vaccine-license-following-severe-adverse-events-in-elderly-patients 2024-12-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/checkpoint-therapeutics-gets-its-first-fda-approval-morningstar 2024-12-13T23:59:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/checkpoint-therapeutics-gets-its-first-fda-approval-morningstar 2024-12-13T23:59:36+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-crinecerfont-for-congenital-adrenal-hyperplasia-hcplive 2024-12-13T23:55:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-crinecerfont-for-congenital-adrenal-hyperplasia-hcplive 2024-12-13T23:55:07+00:00 weekly 0.7 https://trial.medpath.com/news/mpox-vaccine-ready-for-clinical-trial-chinadaily-com-cn 2024-12-13T23:25:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mpox-vaccine-ready-for-clinical-trial-chinadaily-com-cn 2024-12-13T23:25:16+00:00 weekly 0.7 https://trial.medpath.com/news/viridian-therapeutics-to-webcast-veligrotug-phase-3-thrive-2-topline-results-yahoo-finance 2024-12-13T23:13:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viridian-therapeutics-to-webcast-veligrotug-phase-3-thrive-2-topline-results-yahoo-finance 2024-12-13T23:13:27+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-service-brightpath-bio-and-cellistic-announces-process-development-and 2024-12-13T23:02:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-service-brightpath-bio-and-cellistic-announces-process-development-and 2024-12-13T23:02:21+00:00 weekly 0.7 https://trial.medpath.com/news/study-promising-drug-for-treating-rare-childhood-cancer-qna 2024-12-13T22:26:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-promising-drug-for-treating-rare-childhood-cancer-qna 2024-12-13T22:26:22+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-director-ramiro-guerrero-buys-99998-in-stock-investing-com 2024-12-13T22:25:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-director-ramiro-guerrero-buys-99998-in-stock-investing-com 2024-12-13T22:25:40+00:00 weekly 0.7 https://trial.medpath.com/news/supportive-care-helps-manage-aes-with-teclistamab-in-r-r-multiple-myeloma 2024-12-13T22:19:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/supportive-care-helps-manage-aes-with-teclistamab-in-r-r-multiple-myeloma 2024-12-13T22:19:04+00:00 weekly 0.7 https://trial.medpath.com/news/center-for-biostatistics-in-aids-research-cbar-2024-highlights 2024-12-13T22:03:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/center-for-biostatistics-in-aids-research-cbar-2024-highlights 2024-12-13T22:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/t-dxd-preserves-qol-neurological-function-in-her2-metastatic-breast-cancer 2024-12-13T21:46:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/t-dxd-preserves-qol-neurological-function-in-her2-metastatic-breast-cancer 2024-12-13T21:46:32+00:00 weekly 0.7 https://trial.medpath.com/news/helping-kids-with-cancer-speak-for-the-supportive-care-they-need 2024-12-13T21:17:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/helping-kids-with-cancer-speak-for-the-supportive-care-they-need 2024-12-13T21:17:13+00:00 weekly 0.7 https://trial.medpath.com/news/stimulating-a-nerve-the-long-winding-road-of-vagus-nerve-stimulation-as-a-treatment 2024-12-13T21:14:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stimulating-a-nerve-the-long-winding-road-of-vagus-nerve-stimulation-as-a-treatment 2024-12-13T21:14:26+00:00 weekly 0.7 https://trial.medpath.com/news/study-finds-sglt-2-inhibitor-may-slow-progression-of-diabetic-retinopathy-in-patients-with 2024-12-13T21:14:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-finds-sglt-2-inhibitor-may-slow-progression-of-diabetic-retinopathy-in-patients-with 2024-12-13T21:14:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-revokes-emergency-use-authorization-eua-for-bebtelovimab-for-the-treatment-of-covid-19 2024-12-13T21:12:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-revokes-emergency-use-authorization-eua-for-bebtelovimab-for-the-treatment-of-covid-19 2024-12-13T21:12:25+00:00 weekly 0.7 https://trial.medpath.com/news/fda-revokes-eua-for-sotrovimab-for-the-treatment-of-covid-19 2024-12-13T21:12:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-revokes-eua-for-sotrovimab-for-the-treatment-of-covid-19 2024-12-13T21:12:24+00:00 weekly 0.7 https://trial.medpath.com/news/giroctocogene-fitelparvovec-prevents-hem-a-bleeds-new-trial-data 2024-12-13T20:41:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/giroctocogene-fitelparvovec-prevents-hem-a-bleeds-new-trial-data 2024-12-13T20:41:13+00:00 weekly 0.7 https://trial.medpath.com/news/gileads-seladelpar-receives-positive-chmp-opinion-for-primary-biliary-cholangitis 2024-12-13T20:31:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gileads-seladelpar-receives-positive-chmp-opinion-for-primary-biliary-cholangitis 2024-12-13T20:31:11+00:00 weekly 0.7 https://trial.medpath.com/news/niraparib-dostarlimab-shows-promise-in-brca-er-her2-breast-cancer 2024-12-13T20:29:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/niraparib-dostarlimab-shows-promise-in-brca-er-her2-breast-cancer 2024-12-13T20:29:57+00:00 weekly 0.7 https://trial.medpath.com/news/say-that-again-cooling-devices-may-prevent-hearing-loss-inventum 2024-12-13T20:18:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/say-that-again-cooling-devices-may-prevent-hearing-loss-inventum 2024-12-13T20:18:29+00:00 weekly 0.7 https://trial.medpath.com/news/fda-revokes-eua-for-evusheld-tixagevimab-co-packaged-with-cilgavimab 2024-12-13T20:12:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-revokes-eua-for-evusheld-tixagevimab-co-packaged-with-cilgavimab 2024-12-13T20:12:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-oral-antibiotic-to-treat-uncomplicated-utis-drug-discovery-news 2024-12-13T20:05:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-oral-antibiotic-to-treat-uncomplicated-utis-drug-discovery-news 2024-12-13T20:05:16+00:00 weekly 0.7 https://trial.medpath.com/news/perioperative-atezolizumab-falls-short-in-tnbc-targeted-oncology 2024-12-13T19:58:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/perioperative-atezolizumab-falls-short-in-tnbc-targeted-oncology 2024-12-13T19:58:39+00:00 weekly 0.7 https://trial.medpath.com/news/hiv-drug-based-in-research-by-sundquist-lab-is-sci-newswise 2024-12-13T19:56:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hiv-drug-based-in-research-by-sundquist-lab-is-sci-newswise 2024-12-13T19:56:54+00:00 weekly 0.7 https://trial.medpath.com/news/response-rates-were-improved-for-camrelizumab-chemo-vs-chemo-in-tnbc 2024-12-13T19:47:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/response-rates-were-improved-for-camrelizumab-chemo-vs-chemo-in-tnbc 2024-12-13T19:47:08+00:00 weekly 0.7 https://trial.medpath.com/news/zest-trial-offers-insights-for-using-ctdna-to-predict-breast-cancer-recurrence 2024-12-13T19:19:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zest-trial-offers-insights-for-using-ctdna-to-predict-breast-cancer-recurrence 2024-12-13T19:19:09+00:00 weekly 0.7 https://trial.medpath.com/news/talquetamab-step-up-dosing-strategies-and-crs-monitoring-targeted-oncology 2024-12-13T19:18:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/talquetamab-step-up-dosing-strategies-and-crs-monitoring-targeted-oncology 2024-12-13T19:18:27+00:00 weekly 0.7 https://trial.medpath.com/news/csl-receives-positive-chmp-opinion-for-garadacimab-in-hereditary-angioedema-hae 2024-12-13T18:40:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/csl-receives-positive-chmp-opinion-for-garadacimab-in-hereditary-angioedema-hae 2024-12-13T18:40:12+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-recommends-approval-of-galderma-s-nemolizumab-for-moderate-to-severe-atopic 2024-12-13T18:18:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chmp-recommends-approval-of-galderma-s-nemolizumab-for-moderate-to-severe-atopic 2024-12-13T18:18:40+00:00 weekly 0.7 https://trial.medpath.com/news/orca-t-leads-to-retrospective-os-improvement-in-high-risk-hematologic-malignancies 2024-12-13T18:13:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/orca-t-leads-to-retrospective-os-improvement-in-high-risk-hematologic-malignancies 2024-12-13T18:13:33+00:00 weekly 0.7 https://trial.medpath.com/news/high-dose-bi655064-shows-promising-results-in-improving-renal-outcomes-for-people 2024-12-13T17:53:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/high-dose-bi655064-shows-promising-results-in-improving-renal-outcomes-for-people 2024-12-13T17:53:19+00:00 weekly 0.7 https://trial.medpath.com/news/inupadenant-deprioritised-by-iteos-in-favour-of-pipeline-tigit-therapy 2024-12-13T17:44:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inupadenant-deprioritised-by-iteos-in-favour-of-pipeline-tigit-therapy 2024-12-13T17:44:15+00:00 weekly 0.7 https://trial.medpath.com/news/action-centers-collaborate-with-johnson-johnson-medtech-to-secure-fda-labeling-for 2024-12-13T17:43:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/action-centers-collaborate-with-johnson-johnson-medtech-to-secure-fda-labeling-for 2024-12-13T17:43:21+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-drug-and-medical-trials-revolutionizing-care-for-patients-in-brampton-and-beyond 2024-12-13T17:42:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-drug-and-medical-trials-revolutionizing-care-for-patients-in-brampton-and-beyond 2024-12-13T17:42:01+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-biosciences-stock-hits-52-week-low-at-25-16-investing-com 2024-12-13T17:35:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ideaya-biosciences-stock-hits-52-week-low-at-25-16-investing-com 2024-12-13T17:35:51+00:00 weekly 0.7 https://trial.medpath.com/news/tam-anh-general-hospital-joins-global-effort-to-advance-cancer-treatment-with-vista-1-clinical-trial 2024-12-13T17:28:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tam-anh-general-hospital-joins-global-effort-to-advance-cancer-treatment-with-vista-1-clinical-trial 2024-12-13T17:28:05+00:00 weekly 0.7 https://trial.medpath.com/news/eu-drugs-regulator-backs-mounjaro-s-sleep-apnea-use-without-fresh-approval-for-lilly 2024-12-13T17:24:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-drugs-regulator-backs-mounjaro-s-sleep-apnea-use-without-fresh-approval-for-lilly 2024-12-13T17:24:39+00:00 weekly 0.7 https://trial.medpath.com/news/postoperative-radiation-improves-hrqol-over-endocrine-therapy-in-breast-cancer 2024-12-13T17:18:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/postoperative-radiation-improves-hrqol-over-endocrine-therapy-in-breast-cancer 2024-12-13T17:18:17+00:00 weekly 0.7 https://trial.medpath.com/news/repare-therapeutics-shares-drop-38-following-phase-1-trial-results-yahoo-finance 2024-12-13T17:10:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/repare-therapeutics-shares-drop-38-following-phase-1-trial-results-yahoo-finance 2024-12-13T17:10:08+00:00 weekly 0.7 https://trial.medpath.com/news/sibylle-loibl-on-primary-results-of-the-randomized-phase-iii-padma-study-in-her2 2024-12-13T16:41:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sibylle-loibl-on-primary-results-of-the-randomized-phase-iii-padma-study-in-her2 2024-12-13T16:41:36+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-approves-imetelstat-for-transfusion-dependent-anemia-in-lower-risk-mds 2024-12-13T16:36:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-commission-approves-imetelstat-for-transfusion-dependent-anemia-in-lower-risk-mds 2024-12-13T16:36:45+00:00 weekly 0.7 https://trial.medpath.com/news/pharmaceutical-business-updates-from-november-2024 2024-12-13T16:32:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmaceutical-business-updates-from-november-2024 2024-12-13T16:32:52+00:00 weekly 0.7 https://trial.medpath.com/news/dream-hf-trial-sheds-positive-light-on-revascor-for-ischemic-hf-clinical-trials-arena 2024-12-13T16:29:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dream-hf-trial-sheds-positive-light-on-revascor-for-ischemic-hf-clinical-trials-arena 2024-12-13T16:29:33+00:00 weekly 0.7 https://trial.medpath.com/news/targeting-peptide-antigens-using-a-multiallelic-mhc-i-binding-system-nature-biotechnology 2024-12-13T16:19:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/targeting-peptide-antigens-using-a-multiallelic-mhc-i-binding-system-nature-biotechnology 2024-12-13T16:19:47+00:00 weekly 0.7 https://trial.medpath.com/news/intermittent-or-continuous-panitumumab-plus-folfiri-in-first-line-treatment-of-ras-and 2024-12-13T15:41:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intermittent-or-continuous-panitumumab-plus-folfiri-in-first-line-treatment-of-ras-and 2024-12-13T15:41:36+00:00 weekly 0.7 https://trial.medpath.com/news/100-mg-bezuclastinib-improves-symptoms-biomarkers-in-non-advanced-systemic-mastocytosis 2024-12-13T15:21:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/100-mg-bezuclastinib-improves-symptoms-biomarkers-in-non-advanced-systemic-mastocytosis 2024-12-13T15:21:46+00:00 weekly 0.7 https://trial.medpath.com/news/brain-tumors-hijack-circadian-rhythms-to-accelerate-growth-inside-precision-medicine 2024-12-13T15:15:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brain-tumors-hijack-circadian-rhythms-to-accelerate-growth-inside-precision-medicine 2024-12-13T15:15:18+00:00 weekly 0.7 https://trial.medpath.com/news/walgreens-boots-alliance-inc-wba-launches-clinical-trials-patient-advisory-board 2024-12-13T15:12:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/walgreens-boots-alliance-inc-wba-launches-clinical-trials-patient-advisory-board 2024-12-13T15:12:34+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-splicebio-s-ind-application-to-begin-stargardt-disease-therapy-trial 2024-12-13T15:10:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-splicebio-s-ind-application-to-begin-stargardt-disease-therapy-trial 2024-12-13T15:10:01+00:00 weekly 0.7 https://trial.medpath.com/news/launch-of-largest-ever-study-tracking-chikungunya-burden-in-east-africa 2024-12-13T14:46:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/launch-of-largest-ever-study-tracking-chikungunya-burden-in-east-africa 2024-12-13T14:46:20+00:00 weekly 0.7 https://trial.medpath.com/news/stockport-grandad-free-from-blood-cancer-after-being-on-a-clinical-trial-at-the-christie 2024-12-13T14:29:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stockport-grandad-free-from-blood-cancer-after-being-on-a-clinical-trial-at-the-christie 2024-12-13T14:29:58+00:00 weekly 0.7 https://trial.medpath.com/news/single-cell-rna-sequencing-reveals-transcriptional-changes-in-circulating-immune-cells 2024-12-13T14:16:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/single-cell-rna-sequencing-reveals-transcriptional-changes-in-circulating-immune-cells 2024-12-13T14:16:36+00:00 weekly 0.7 https://trial.medpath.com/news/maic-points-to-improved-os-with-momelotinib-in-ruxolitinib-pretreated-myelofibrosis 2024-12-13T14:06:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maic-points-to-improved-os-with-momelotinib-in-ruxolitinib-pretreated-myelofibrosis 2024-12-13T14:06:51+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-s-omvoh-scores-landmark-chmp-backing-for-crohn-s-disease-first-to-show-stock-titan 2024-12-13T13:51:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-s-omvoh-scores-landmark-chmp-backing-for-crohn-s-disease-first-to-show-stock-titan 2024-12-13T13:51:45+00:00 weekly 0.7 https://trial.medpath.com/news/innovative-biologic-prefilled-syringe-approved-in-eu-european-pharmaceutical-review 2024-12-13T13:36:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovative-biologic-prefilled-syringe-approved-in-eu-european-pharmaceutical-review 2024-12-13T13:36:34+00:00 weekly 0.7 https://trial.medpath.com/news/ub-studies-on-ms-patients-reveal-how-paramagnetic-rim-lesions-evolve-what-they-mean-for 2024-12-13T13:26:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ub-studies-on-ms-patients-reveal-how-paramagnetic-rim-lesions-evolve-what-they-mean-for 2024-12-13T13:26:15+00:00 weekly 0.7 https://trial.medpath.com/news/multimodal-machine-learning-model-effective-at-predicting-response-to-cdk4-6-inhibitors 2024-12-13T13:19:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/multimodal-machine-learning-model-effective-at-predicting-response-to-cdk4-6-inhibitors 2024-12-13T13:19:11+00:00 weekly 0.7 https://trial.medpath.com/news/ben-samelson-jones-md-phd-on-confirming-the-safety-of-pfizer-s-hemophilia-b-gene 2024-12-13T13:07:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ben-samelson-jones-md-phd-on-confirming-the-safety-of-pfizer-s-hemophilia-b-gene 2024-12-13T13:07:49+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-advances-corporate-growth-strategy-through-sanofi-partnership-including 2024-12-13T13:04:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novavax-advances-corporate-growth-strategy-through-sanofi-partnership-including 2024-12-13T13:04:54+00:00 weekly 0.7 https://trial.medpath.com/news/dcgi-pushes-fast-track-approval-for-rare-disease-drugs-prioritizes-patient-access 2024-12-13T12:58:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dcgi-pushes-fast-track-approval-for-rare-disease-drugs-prioritizes-patient-access 2024-12-13T12:58:56+00:00 weekly 0.7 https://trial.medpath.com/news/newron-and-ea-pharma-a-subsidiary-of-eisai-co-ltd-announce-license-agreement-for 2024-12-13T12:57:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/newron-and-ea-pharma-a-subsidiary-of-eisai-co-ltd-announce-license-agreement-for 2024-12-13T12:57:00+00:00 weekly 0.7 https://trial.medpath.com/news/sec-form-10-q-filed-by-galera-therapeutics-inc-quantisnow 2024-12-13T12:31:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sec-form-10-q-filed-by-galera-therapeutics-inc-quantisnow 2024-12-13T12:31:16+00:00 weekly 0.7 https://trial.medpath.com/news/geron-corp-gern-receives-positive-chmp-opinion-for-rytelo-in-t-gurufocus 2024-12-13T12:13:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/geron-corp-gern-receives-positive-chmp-opinion-for-rytelo-in-t-gurufocus 2024-12-13T12:13:47+00:00 weekly 0.7 https://trial.medpath.com/news/the-board-of-directors-decision-on-a-new-execution-strategy-and-prioritisation-of-clinical 2024-12-13T11:27:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-board-of-directors-decision-on-a-new-execution-strategy-and-prioritisation-of-clinical 2024-12-13T11:27:18+00:00 weekly 0.7 https://trial.medpath.com/news/multispecific-antibodies-market-set-to-exceed-40-billion-as-next-generation-cancer-therapies-advance 2024-12-13T11:24:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/multispecific-antibodies-market-set-to-exceed-40-billion-as-next-generation-cancer-therapies-advance 2024-12-13T11:24:39+00:00 weekly 0.7 https://trial.medpath.com/news/cost-barriers-lead-to-medication-non-adherence-in-17-8-of-us-asthma-patients-study-reveals 2024-12-13T11:19:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cost-barriers-lead-to-medication-non-adherence-in-17-8-of-us-asthma-patients-study-reveals 2024-12-13T11:19:40+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-agreement-with-fda-on-factors-for-accelerated-approval-process 2024-12-13T10:30:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diamyd-medical-agreement-with-fda-on-factors-for-accelerated-approval-process 2024-12-13T10:30:07+00:00 weekly 0.7 https://trial.medpath.com/news/ionis-has-much-riding-on-drug-approval-and-major-strategic-shift-stat-news 2024-12-13T09:34:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ionis-has-much-riding-on-drug-approval-and-major-strategic-shift-stat-news 2024-12-13T09:34:07+00:00 weekly 0.7 https://trial.medpath.com/news/tyra-300-shows-promise-in-urothelial-cancer-treatment-with-projected-63m-revenue-by-2036 2024-12-13T09:07:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tyra-300-shows-promise-in-urothelial-cancer-treatment-with-projected-63m-revenue-by-2036 2024-12-13T09:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/adalimumab-biosimilars-drive-45-drop-in-net-spending-despite-limited-market-share 2024-12-13T08:53:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adalimumab-biosimilars-drive-45-drop-in-net-spending-despite-limited-market-share 2024-12-13T08:53:36+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-randomized-trial-complementary-analysis-of-immune-persistence-3-6-years-after-priming 2024-12-13T08:34:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-iii-randomized-trial-complementary-analysis-of-immune-persistence-3-6-years-after-priming 2024-12-13T08:34:07+00:00 weekly 0.7 https://trial.medpath.com/news/less-frequent-elfabrio-ert-regimen-for-fabry-up-for-eu-approval 2024-12-13T07:38:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/less-frequent-elfabrio-ert-regimen-for-fabry-up-for-eu-approval 2024-12-13T07:38:49+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-s-tolebrutinib-gets-fda-breakthrough-therapy-designation-for-nrspms 2024-12-13T07:29:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-s-tolebrutinib-gets-fda-breakthrough-therapy-designation-for-nrspms 2024-12-13T07:29:15+00:00 weekly 0.7 https://trial.medpath.com/news/rezolute-s-clinical-progress-and-market-potential-highlighted-in-swot-analysis 2024-12-13T06:11:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rezolute-s-clinical-progress-and-market-potential-highlighted-in-swot-analysis 2024-12-13T06:11:00+00:00 weekly 0.7 https://trial.medpath.com/news/2024-s-most-impactful-gene-therapy-developments-from-cost-challenges-to-access-solutions 2024-12-13T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2024-s-most-impactful-gene-therapy-developments-from-cost-challenges-to-access-solutions 2024-12-13T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/missouri-healthcare-system-shows-resilience-amid-historic-medicaid-expansion-survey-reveals 2024-12-13T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/missouri-healthcare-system-shows-resilience-amid-historic-medicaid-expansion-survey-reveals 2024-12-13T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/accropeutics-inc-announces-u-s-fda-clearance-of-ind-application-for-ripk2-inhibitor-ac-101 2024-12-13T05:31:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/accropeutics-inc-announces-u-s-fda-clearance-of-ind-application-for-ripk2-inhibitor-ac-101 2024-12-13T05:31:58+00:00 weekly 0.7 https://trial.medpath.com/news/biomarker-guided-therapies-transform-treatment-landscape-across-multiple-cancers 2024-12-13T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomarker-guided-therapies-transform-treatment-landscape-across-multiple-cancers 2024-12-13T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/briacell-2024-sabcs-r-poster-highlights-ability-of-bria-imttm-regimen-to-increase-cancer-fighting-immune-cells-in-metastatic-breast-cancer 2024-12-13T04:50:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/briacell-2024-sabcs-r-poster-highlights-ability-of-bria-imttm-regimen-to-increase-cancer-fighting-immune-cells-in-metastatic-breast-cancer 2024-12-13T04:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-treatment-strategies-emerge-for-egfr-mutated-nsclc-as-amivantamab-shows-promise 2024-12-13T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-treatment-strategies-emerge-for-egfr-mutated-nsclc-as-amivantamab-shows-promise 2024-12-13T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-faces-lawsuit-from-padlock-therapeutics-investors-over-milestone-payment-dispute 2024-12-13T03:46:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-faces-lawsuit-from-padlock-therapeutics-investors-over-milestone-payment-dispute 2024-12-13T03:46:00+00:00 weekly 0.7 https://trial.medpath.com/news/alphamab-oncology-presents-the-phase-ii-clinical-data-of-kn046-in-combination-with 2024-12-13T03:25:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alphamab-oncology-presents-the-phase-ii-clinical-data-of-kn046-in-combination-with 2024-12-13T03:25:34+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-acquires-nimble-therapeutics-for-200m-expanding-oral-immunology-pipeline 2024-12-13T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-acquires-nimble-therapeutics-for-200m-expanding-oral-immunology-pipeline 2024-12-13T03:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/solventum-pioneers-novel-tooth-based-randomization-approach-in-dental-clinical-trials-using-zelta-platform 2024-12-13T02:46:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/solventum-pioneers-novel-tooth-based-randomization-approach-in-dental-clinical-trials-using-zelta-platform 2024-12-13T02:46:53+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-lack-of-clinical-evidence-behind-popular-dietary-supplements-health-claims 2024-12-13T02:24:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-lack-of-clinical-evidence-behind-popular-dietary-supplements-health-claims 2024-12-13T02:24:20+00:00 weekly 0.7 https://trial.medpath.com/news/nyxoah-expands-global-reach-genio-neurostimulation-therapy-for-osa-launches-in-middle-east-and-england 2024-12-13T01:49:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nyxoah-expands-global-reach-genio-neurostimulation-therapy-for-osa-launches-in-middle-east-and-england 2024-12-13T01:49:32+00:00 weekly 0.7 https://trial.medpath.com/news/most-patients-with-intermediate-risk-breast-cancer-may-safely-avoid-chest-wall-irradiation 2024-12-13T01:34:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/most-patients-with-intermediate-risk-breast-cancer-may-safely-avoid-chest-wall-irradiation 2024-12-13T01:34:09+00:00 weekly 0.7 https://trial.medpath.com/news/ars-pharmaceuticals-announces-filings-for-approval-of-neffy-r-in-china-japan-and-australia 2024-12-13T01:33:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ars-pharmaceuticals-announces-filings-for-approval-of-neffy-r-in-china-japan-and-australia 2024-12-13T01:33:47+00:00 weekly 0.7 https://trial.medpath.com/news/interview-mediwhale-pushes-for-fda-approval-to-bring-ai-retinal-scan-to-us-cardiovascular-kbr 2024-12-13T01:01:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/interview-mediwhale-pushes-for-fda-approval-to-bring-ai-retinal-scan-to-us-cardiovascular-kbr 2024-12-13T01:01:59+00:00 weekly 0.7 https://trial.medpath.com/news/fda-revokes-euas-for-four-monoclonal-antibody-products 2024-12-13T00:11:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-revokes-euas-for-four-monoclonal-antibody-products 2024-12-13T00:11:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-and-biomarker-analyses-of-shr-1701-combined-with-famitinib-in-patients-with-nature 2024-12-13T00:07:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-and-biomarker-analyses-of-shr-1701-combined-with-famitinib-in-patients-with-nature 2024-12-13T00:07:57+00:00 weekly 0.7 https://trial.medpath.com/news/the-daily-hit-december-12-2024-green-market-report 2024-12-13T00:06:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-daily-hit-december-12-2024-green-market-report 2024-12-13T00:06:05+00:00 weekly 0.7 https://trial.medpath.com/news/solid-biosciences-positioned-for-next-gen-duchenne-muscular-dystrophy-treatment-success-analyst 2024-12-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/solid-biosciences-positioned-for-next-gen-duchenne-muscular-dystrophy-treatment-success-analyst 2024-12-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/university-of-wollongong-secures-500k-grant-to-advance-resectassisttm-cancer-device-for-pancreatic-tumors 2024-12-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/university-of-wollongong-secures-500k-grant-to-advance-resectassisttm-cancer-device-for-pancreatic-tumors 2024-12-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bicycle-therapeutics-announces-data-updates-across-zelenectide-pevedotin-program-and 2024-12-12T23:41:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bicycle-therapeutics-announces-data-updates-across-zelenectide-pevedotin-program-and 2024-12-12T23:41:49+00:00 weekly 0.7 https://trial.medpath.com/news/2024-sabcs-results-unveiled-for-the-phase-iii-study-of-disitamab-vedotin-in-treating 2024-12-12T23:40:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2024-sabcs-results-unveiled-for-the-phase-iii-study-of-disitamab-vedotin-in-treating 2024-12-12T23:40:43+00:00 weekly 0.7 https://trial.medpath.com/news/takeda-spotlights-high-value-late-stage-pipeline-accelerating-the-development-of-biospace 2024-12-12T23:29:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/takeda-spotlights-high-value-late-stage-pipeline-accelerating-the-development-of-biospace 2024-12-12T23:29:40+00:00 weekly 0.7 https://trial.medpath.com/news/keros-shares-collapse-on-unanticipated-setback-for-lung-disease-drug-biopharma-dive 2024-12-12T23:15:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/keros-shares-collapse-on-unanticipated-setback-for-lung-disease-drug-biopharma-dive 2024-12-12T23:15:58+00:00 weekly 0.7 https://trial.medpath.com/news/scott-tagawa-md-highlights-phase-3-trial-of-177lu-tlx591-in-mcrpc-urology-times 2024-12-12T23:03:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scott-tagawa-md-highlights-phase-3-trial-of-177lu-tlx591-in-mcrpc-urology-times 2024-12-12T23:03:35+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-s-novel-mash-treatment-combination-clesacostat-ervogastat-projects-16m-revenue-by-2036 2024-12-12T22:59:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-s-novel-mash-treatment-combination-clesacostat-ervogastat-projects-16m-revenue-by-2036 2024-12-12T22:59:33+00:00 weekly 0.7 https://trial.medpath.com/news/improving-access-to-nivolumab-by-lowering-age-restrictions-in-clinical-trial 2024-12-12T22:26:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/improving-access-to-nivolumab-by-lowering-age-restrictions-in-clinical-trial 2024-12-12T22:26:59+00:00 weekly 0.7 https://trial.medpath.com/news/corcept-s-als-drug-trial-disappoints-but-zero-deaths-in-high-dose-group-firstword-pharma 2024-12-12T21:43:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corcept-s-als-drug-trial-disappoints-but-zero-deaths-in-high-dose-group-firstword-pharma 2024-12-12T21:43:07+00:00 weekly 0.7 https://trial.medpath.com/news/repare-therapeutics-announces-positive-results-of-the-lunresertib-and-camonsertib-stock-titan 2024-12-12T21:27:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/repare-therapeutics-announces-positive-results-of-the-lunresertib-and-camonsertib-stock-titan 2024-12-12T21:27:10+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-at-the-neuro-target-myotonic-dystrophy-mcgill-reporter 2024-12-12T21:18:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-at-the-neuro-target-myotonic-dystrophy-mcgill-reporter 2024-12-12T21:18:48+00:00 weekly 0.7 https://trial.medpath.com/news/corcept-s-korlym-shows-breakthrough-results-in-phase-4-diabetes-cushing-s-trial-hits 2024-12-12T21:15:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corcept-s-korlym-shows-breakthrough-results-in-phase-4-diabetes-cushing-s-trial-hits 2024-12-12T21:15:40+00:00 weekly 0.7 https://trial.medpath.com/news/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-globenewswire 2024-12-12T21:11:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immune-complex-membranoproliferative-glomerulonephritis-ic-mpgn-globenewswire 2024-12-12T21:11:48+00:00 weekly 0.7 https://trial.medpath.com/news/ascendis-pharma-s-transcon-hgh-scores-fda-filing-acceptance-after-superior-stock-titan 2024-12-12T21:08:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascendis-pharma-s-transcon-hgh-scores-fda-filing-acceptance-after-superior-stock-titan 2024-12-12T21:08:41+00:00 weekly 0.7 https://trial.medpath.com/news/ongoing-trials-may-elucidate-mosunetuzumab-efficacy-in-follicular-lymphoma 2024-12-12T21:04:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ongoing-trials-may-elucidate-mosunetuzumab-efficacy-in-follicular-lymphoma 2024-12-12T21:04:33+00:00 weekly 0.7 https://trial.medpath.com/news/innocan-pharma-provides-its-annual-state-of-research-and-development-update-for-2024 2024-12-12T21:03:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innocan-pharma-provides-its-annual-state-of-research-and-development-update-for-2024 2024-12-12T21:03:54+00:00 weekly 0.7 https://trial.medpath.com/news/defloria-s-advances-cannabis-based-autism-drug-through-early-trial-green-market-report 2024-12-12T20:20:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/defloria-s-advances-cannabis-based-autism-drug-through-early-trial-green-market-report 2024-12-12T20:20:23+00:00 weekly 0.7 https://trial.medpath.com/news/pitt-led-study-likely-to-change-standard-of-care-strokes-upmc 2024-12-12T20:19:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pitt-led-study-likely-to-change-standard-of-care-strokes-upmc 2024-12-12T20:19:58+00:00 weekly 0.7 https://trial.medpath.com/news/online-vs-face-to-face-pulmonary-rehabilitation-for-copd-patients-a-randomized-controlled-trial 2024-12-12T20:12:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/online-vs-face-to-face-pulmonary-rehabilitation-for-copd-patients-a-randomized-controlled-trial 2024-12-12T20:12:00+00:00 weekly 0.7 https://trial.medpath.com/news/shine-study-developing-an-intervention-for-safe-hospital-insulin-use-for-older-or-frail-adults-plos 2024-12-12T20:08:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shine-study-developing-an-intervention-for-safe-hospital-insulin-use-for-older-or-frail-adults-plos 2024-12-12T20:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/sean-m-healey-amg-center-announces-updates-to-healey-als-platform-trial-master-protocol 2024-12-12T19:26:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sean-m-healey-amg-center-announces-updates-to-healey-als-platform-trial-master-protocol 2024-12-12T19:26:26+00:00 weekly 0.7 https://trial.medpath.com/news/new-partnership-between-cytophage-orthopedic-innovation-centre-targets-prosthetic 2024-12-12T18:50:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-partnership-between-cytophage-orthopedic-innovation-centre-targets-prosthetic 2024-12-12T18:50:13+00:00 weekly 0.7 https://trial.medpath.com/news/targeted-alpha-therapy-market-clinical-trials-proprietary-technologies-insight-biospace 2024-12-12T18:37:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/targeted-alpha-therapy-market-clinical-trials-proprietary-technologies-insight-biospace 2024-12-12T18:37:25+00:00 weekly 0.7 https://trial.medpath.com/news/autologous-stem-cell-transplantation-may-not-improve-survival-in-patients-with-mcl 2024-12-12T18:35:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/autologous-stem-cell-transplantation-may-not-improve-survival-in-patients-with-mcl 2024-12-12T18:35:56+00:00 weekly 0.7 https://trial.medpath.com/news/private-medicare-plans-required-to-cover-biogen-s-als-drug-says-us-agency 2024-12-12T17:51:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/private-medicare-plans-required-to-cover-biogen-s-als-drug-says-us-agency 2024-12-12T17:51:00+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-completes-acquisition-of-aliada-therapeutics-pharmaceutical-executive 2024-12-12T17:14:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-completes-acquisition-of-aliada-therapeutics-pharmaceutical-executive 2024-12-12T17:14:07+00:00 weekly 0.7 https://trial.medpath.com/news/kidney-compass-parasol-findings-and-implications-for-fsgs-hcplive 2024-12-12T17:10:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kidney-compass-parasol-findings-and-implications-for-fsgs-hcplive 2024-12-12T17:10:09+00:00 weekly 0.7 https://trial.medpath.com/news/commands-trial-luspatercept-long-term-transfusion-benefit-compared-with-epoetin-alfa 2024-12-12T16:55:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/commands-trial-luspatercept-long-term-transfusion-benefit-compared-with-epoetin-alfa 2024-12-12T16:55:00+00:00 weekly 0.7 https://trial.medpath.com/news/highest-risk-cll-patients-may-benefit-from-car-t-with-btk-inhibitor-clinical-trials-arena 2024-12-12T16:37:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/highest-risk-cll-patients-may-benefit-from-car-t-with-btk-inhibitor-clinical-trials-arena 2024-12-12T16:37:55+00:00 weekly 0.7 https://trial.medpath.com/news/a-randomized-phase-iii-clinical-trial-in-colon-cancer-company-announcement-markets-data 2024-12-12T16:13:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-randomized-phase-iii-clinical-trial-in-colon-cancer-company-announcement-markets-data 2024-12-12T16:13:17+00:00 weekly 0.7 https://trial.medpath.com/news/sobi-announces-fda-acceptance-of-new-drug-application-for-avatrombopag-doptelet 2024-12-12T15:57:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sobi-announces-fda-acceptance-of-new-drug-application-for-avatrombopag-doptelet 2024-12-12T15:57:39+00:00 weekly 0.7 https://trial.medpath.com/news/seaport-therapeutics-sees-success-with-allopregnanolone-prodrug-clinical-trials-arena 2024-12-12T15:43:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/seaport-therapeutics-sees-success-with-allopregnanolone-prodrug-clinical-trials-arena 2024-12-12T15:43:11+00:00 weekly 0.7 https://trial.medpath.com/news/light-therapy-trial-shows-feasibility-of-home-studies-in-parkinson-s 2024-12-12T15:17:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/light-therapy-trial-shows-feasibility-of-home-studies-in-parkinson-s 2024-12-12T15:17:32+00:00 weekly 0.7 https://trial.medpath.com/news/december-12-2024-another-year-of-innovations-and-insights-from-the-nih-pragmatic-trials 2024-12-12T15:02:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/december-12-2024-another-year-of-innovations-and-insights-from-the-nih-pragmatic-trials 2024-12-12T15:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/pdc-line-pharma-presents-primary-clinical-results-from-phase-i-ii-trial-on-pdc-lung01 2024-12-12T14:58:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pdc-line-pharma-presents-primary-clinical-results-from-phase-i-ii-trial-on-pdc-lung01 2024-12-12T14:58:56+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-patina-study-shows-hope-for-hr-her2-cancer-mirage-news 2024-12-12T14:58:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-iii-patina-study-shows-hope-for-hr-her2-cancer-mirage-news 2024-12-12T14:58:46+00:00 weekly 0.7 https://trial.medpath.com/news/egetis-receives-positive-chmp-opinion-for-emcitate-r-tiratricol-for-the-treatment-of-mct8-deficiency 2024-12-12T14:44:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/egetis-receives-positive-chmp-opinion-for-emcitate-r-tiratricol-for-the-treatment-of-mct8-deficiency 2024-12-12T14:44:58+00:00 weekly 0.7 https://trial.medpath.com/news/dr-jitendra-announces-successful-gene-therapy-trial-for-haemophilia-blood-disorder 2024-12-12T14:41:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-jitendra-announces-successful-gene-therapy-trial-for-haemophilia-blood-disorder 2024-12-12T14:41:40+00:00 weekly 0.7 https://trial.medpath.com/news/kiromic-biopharma-reports-32-decrease-in-tumor-volume-eight-months-post-treatment 2024-12-12T14:34:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kiromic-biopharma-reports-32-decrease-in-tumor-volume-eight-months-post-treatment 2024-12-12T14:34:53+00:00 weekly 0.7 https://trial.medpath.com/news/cel-sci-s-cancer-drug-multikine-secures-fda-approval-for-pivotal-study-after-73 2024-12-12T14:34:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cel-sci-s-cancer-drug-multikine-secures-fda-approval-for-pivotal-study-after-73 2024-12-12T14:34:08+00:00 weekly 0.7 https://trial.medpath.com/news/europe-allows-novo-to-include-reduction-of-kidney-disease-in-ozempic-label 2024-12-12T14:33:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/europe-allows-novo-to-include-reduction-of-kidney-disease-in-ozempic-label 2024-12-12T14:33:00+00:00 weekly 0.7 https://trial.medpath.com/news/inupadenant-shows-promise-in-nsclc-phase-2-trial-results-investing-com 2024-12-12T14:31:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inupadenant-shows-promise-in-nsclc-phase-2-trial-results-investing-com 2024-12-12T14:31:36+00:00 weekly 0.7 https://trial.medpath.com/news/alx-oncology-to-host-virtual-event-on-new-clinical-data-from-breast-cancer-study 2024-12-12T14:23:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alx-oncology-to-host-virtual-event-on-new-clinical-data-from-breast-cancer-study 2024-12-12T14:23:00+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-expands-indication-for-impella-heart-pumps-to-treat-pediatric-patients-pr-newswire 2024-12-12T14:19:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-fda-expands-indication-for-impella-heart-pumps-to-treat-pediatric-patients-pr-newswire 2024-12-12T14:19:59+00:00 weekly 0.7 https://trial.medpath.com/news/uae-based-biotech-biosapien-secures-5-5-million-pre-series-a-wamda 2024-12-12T14:19:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uae-based-biotech-biosapien-secures-5-5-million-pre-series-a-wamda 2024-12-12T14:19:25+00:00 weekly 0.7 https://trial.medpath.com/news/aptevo-s-aml-drug-trial-hits-100-remission-rate-complete-cancer-cell-elimination-in 2024-12-12T14:16:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aptevo-s-aml-drug-trial-hits-100-remission-rate-complete-cancer-cell-elimination-in 2024-12-12T14:16:13+00:00 weekly 0.7 https://trial.medpath.com/news/curegene-received-clinical-trial-approval-in-china-for-cg-0255-for-injection 2024-12-12T14:14:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/curegene-received-clinical-trial-approval-in-china-for-cg-0255-for-injection 2024-12-12T14:14:54+00:00 weekly 0.7 https://trial.medpath.com/news/study-finds-quality-of-life-maintained-with-active-monitoring-for-dcis 2024-12-12T14:10:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-finds-quality-of-life-maintained-with-active-monitoring-for-dcis 2024-12-12T14:10:31+00:00 weekly 0.7 https://trial.medpath.com/news/momelotinib-shows-real-world-improvements-in-anemia-symptoms-and-spleen 2024-12-12T14:06:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/momelotinib-shows-real-world-improvements-in-anemia-symptoms-and-spleen 2024-12-12T14:06:12+00:00 weekly 0.7 https://trial.medpath.com/news/iteos-therapeutics-presents-interim-a2a-005-clinical-trial-data-translational-and 2024-12-12T14:04:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iteos-therapeutics-presents-interim-a2a-005-clinical-trial-data-translational-and 2024-12-12T14:04:26+00:00 weekly 0.7 https://trial.medpath.com/news/alzamend-neuro-reports-second-quarter-2025-financial-results-and-provides-update-on 2024-12-12T13:52:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alzamend-neuro-reports-second-quarter-2025-financial-results-and-provides-update-on 2024-12-12T13:52:44+00:00 weekly 0.7 https://trial.medpath.com/news/sk-bioscience-receives-approval-for-global-clinical-trials-of-mrna-japanese-encephalitis 2024-12-12T13:45:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sk-bioscience-receives-approval-for-global-clinical-trials-of-mrna-japanese-encephalitis 2024-12-12T13:45:30+00:00 weekly 0.7 https://trial.medpath.com/news/knight-therapeutics-announces-regulatory-approval-of-tavalisse-r-in-mexico 2024-12-12T13:09:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/knight-therapeutics-announces-regulatory-approval-of-tavalisse-r-in-mexico 2024-12-12T13:09:48+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-s-r-d-approach-scores-dual-wins-against-alexion-s-ultomiris-and-in-lymphoma 2024-12-12T12:46:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regeneron-s-r-d-approach-scores-dual-wins-against-alexion-s-ultomiris-and-in-lymphoma 2024-12-12T12:46:46+00:00 weekly 0.7 https://trial.medpath.com/news/keros-therapeutics-halts-dosing-in-phase-2-trial-of-cibotercept-combination-in-pah 2024-12-12T12:12:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/keros-therapeutics-halts-dosing-in-phase-2-trial-of-cibotercept-combination-in-pah 2024-12-12T12:12:28+00:00 weekly 0.7 https://trial.medpath.com/news/avextra-supports-first-fully-eu-funded-psilocybin-therapy-globenewswire 2024-12-12T12:11:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avextra-supports-first-fully-eu-funded-psilocybin-therapy-globenewswire 2024-12-12T12:11:09+00:00 weekly 0.7 https://trial.medpath.com/news/ryvu-therapeutics-provides-an-update-on-rvu120-phase-ii-program-pr-newswire 2024-12-12T11:22:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ryvu-therapeutics-provides-an-update-on-rvu120-phase-ii-program-pr-newswire 2024-12-12T11:22:05+00:00 weekly 0.7 https://trial.medpath.com/news/ditch-that-itch-early-findings-offer-hope-for-skin-issues-like-rosacea 2024-12-12T11:12:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ditch-that-itch-early-findings-offer-hope-for-skin-issues-like-rosacea 2024-12-12T11:12:03+00:00 weekly 0.7 https://trial.medpath.com/news/blue-lake-biotechnology-reports-additional-promising-clinical-data-from-ongoing-pediatric 2024-12-12T11:10:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blue-lake-biotechnology-reports-additional-promising-clinical-data-from-ongoing-pediatric 2024-12-12T11:10:23+00:00 weekly 0.7 https://trial.medpath.com/news/revbio-receives-both-fda-approval-to-expand-its-clinical-trial-and-cms-reimbursement 2024-12-12T10:27:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/revbio-receives-both-fda-approval-to-expand-its-clinical-trial-and-cms-reimbursement 2024-12-12T10:27:45+00:00 weekly 0.7 https://trial.medpath.com/news/hvivo-unveils-key-covid-19-biomarker-insights-from-human-challenge-study-vox-markets 2024-12-12T10:06:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hvivo-unveils-key-covid-19-biomarker-insights-from-human-challenge-study-vox-markets 2024-12-12T10:06:02+00:00 weekly 0.7 https://trial.medpath.com/news/medicare-drug-price-negotiations-show-limited-impact-on-innovation-study-reveals 2024-12-12T09:12:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicare-drug-price-negotiations-show-limited-impact-on-innovation-study-reveals 2024-12-12T09:12:23+00:00 weekly 0.7 https://trial.medpath.com/news/rna-specialist-proqr-therapeutics-nv-bags-us-8-1m-funding-european-biotechnology 2024-12-12T08:59:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rna-specialist-proqr-therapeutics-nv-bags-us-8-1m-funding-european-biotechnology 2024-12-12T08:59:46+00:00 weekly 0.7 https://trial.medpath.com/news/caris-life-sciences-publishes-large-scale-study-demonstrating-the-critical-role-of-next 2024-12-12T08:08:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/caris-life-sciences-publishes-large-scale-study-demonstrating-the-critical-role-of-next 2024-12-12T08:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/corcept-announces-results-from-phase-2-study-of-dazucorilant-in-patients-with-biospace 2024-12-12T06:49:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corcept-announces-results-from-phase-2-study-of-dazucorilant-in-patients-with-biospace 2024-12-12T06:49:07+00:00 weekly 0.7 https://trial.medpath.com/news/research-scientists-ask-gov-t-to-approve-new-drugs-with-highest-efficacy-of-preventing-hiv 2024-12-12T06:26:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-scientists-ask-gov-t-to-approve-new-drugs-with-highest-efficacy-of-preventing-hiv 2024-12-12T06:26:46+00:00 weekly 0.7 https://trial.medpath.com/news/tils-assessment-emerges-as-powerful-tool-for-personalizing-breast-cancer-treatment-decisions 2024-12-12T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tils-assessment-emerges-as-powerful-tool-for-personalizing-breast-cancer-treatment-decisions 2024-12-12T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/douglas-tsao-maintains-buy-rating-on-xenon-pharmaceuticals-azetukalner 2024-12-12T05:14:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/douglas-tsao-maintains-buy-rating-on-xenon-pharmaceuticals-azetukalner 2024-12-12T05:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/absci-advances-in-ai-driven-drug-development-and-pipeline-updates-at-2024-r-d-day 2024-12-12T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/absci-advances-in-ai-driven-drug-development-and-pipeline-updates-at-2024-r-d-day 2024-12-12T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/leicester-patients-to-get-early-access-to-potentially-life-changing-treatments-as-new-funding 2024-12-12T04:31:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leicester-patients-to-get-early-access-to-potentially-life-changing-treatments-as-new-funding 2024-12-12T04:31:08+00:00 weekly 0.7 https://trial.medpath.com/news/hutchmed-announces-breakthrough-therapy-designation-in-china-for-orpathys-r-and 2024-12-12T04:15:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hutchmed-announces-breakthrough-therapy-designation-in-china-for-orpathys-r-and 2024-12-12T04:15:37+00:00 weekly 0.7 https://trial.medpath.com/news/the-vegf-x-pd-l-1-pipeline-is-growing-and-tnbc-may-benefit-biocentury 2024-12-12T03:26:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-vegf-x-pd-l-1-pipeline-is-growing-and-tnbc-may-benefit-biocentury 2024-12-12T03:26:46+00:00 weekly 0.7 https://trial.medpath.com/news/prospect-lung-trial-aims-to-improve-treatment-for-patients-with-resectable-non-small-cell 2024-12-12T03:01:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prospect-lung-trial-aims-to-improve-treatment-for-patients-with-resectable-non-small-cell 2024-12-12T03:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/doubts-over-landmark-heart-drug-trial-ticagrelor-plato-study-the-bmj 2024-12-12T01:09:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/doubts-over-landmark-heart-drug-trial-ticagrelor-plato-study-the-bmj 2024-12-12T01:09:56+00:00 weekly 0.7 https://trial.medpath.com/news/nec-announces-interim-results-from-phase-1-clinical-trial-of-necvax-neo1 2024-12-12T01:05:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nec-announces-interim-results-from-phase-1-clinical-trial-of-necvax-neo1 2024-12-12T01:05:03+00:00 weekly 0.7 https://trial.medpath.com/news/givlaari-effective-in-aip-patients-often-excluded-from-clinical-trials-porphyria-news 2024-12-12T00:00:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/givlaari-effective-in-aip-patients-often-excluded-from-clinical-trials-porphyria-news 2024-12-12T00:00:03+00:00 weekly 0.7 https://trial.medpath.com/news/boundless-bio-announces-pipeline-and-leadership-updates 2024-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boundless-bio-announces-pipeline-and-leadership-updates 2024-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ror1-a-promising-target-for-cancer-therapy 2024-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ror1-a-promising-target-for-cancer-therapy 2024-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/isatuximab-irfc-sarclisa-approved-for-multiple-myeloma-treatment 2024-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/isatuximab-irfc-sarclisa-approved-for-multiple-myeloma-treatment 2024-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ladrx-plans-nda-submission-for-aldoxorubicin-under-505-b-2-pathway 2024-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ladrx-plans-nda-submission-for-aldoxorubicin-under-505-b-2-pathway 2024-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/weight-loss-drugs-may-also-treat-addiction-alzheimers-and-heart-disease 2024-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weight-loss-drugs-may-also-treat-addiction-alzheimers-and-heart-disease 2024-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-initiates-phase-i-study-with-sos1-inhibitor-for-advanced-kras-mutated-tumours 2024-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-initiates-phase-i-study-with-sos1-inhibitor-for-advanced-kras-mutated-tumours 2024-12-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/how-revolutionary-ucsf-study-hopes-to-help-people-with-traumatic-brain-injuries 2024-12-11T23:58:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-revolutionary-ucsf-study-hopes-to-help-people-with-traumatic-brain-injuries 2024-12-11T23:58:21+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-sees-bright-future-for-registry-based-randomized-clinical-trials 2024-12-11T23:34:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-sees-bright-future-for-registry-based-randomized-clinical-trials 2024-12-11T23:34:11+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-ceo-bourla-prevails-against-starboard-s-1b-activist-challenge 2024-12-11T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-ceo-bourla-prevails-against-starboard-s-1b-activist-challenge 2024-12-11T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-haven-biopharma-firm-veradermics-raises-75m-in-series-b-financing-round 2024-12-11T22:33:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-haven-biopharma-firm-veradermics-raises-75m-in-series-b-financing-round 2024-12-11T22:33:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-neffy-new-nasal-spray-to-treat-severe-allergic-reactions-el-estoque 2024-12-11T22:28:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-neffy-new-nasal-spray-to-treat-severe-allergic-reactions-el-estoque 2024-12-11T22:28:51+00:00 weekly 0.7 https://trial.medpath.com/news/with-new-data-lilly-sets-pace-for-next-wave-of-breast-cancer-drugs-biopharma-dive 2024-12-11T22:27:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/with-new-data-lilly-sets-pace-for-next-wave-of-breast-cancer-drugs-biopharma-dive 2024-12-11T22:27:04+00:00 weekly 0.7 https://trial.medpath.com/news/study-uses-ai-to-cast-light-on-harmful-drug-drug-interactions-vumc-news 2024-12-11T21:52:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-uses-ai-to-cast-light-on-harmful-drug-drug-interactions-vumc-news 2024-12-11T21:52:41+00:00 weekly 0.7 https://trial.medpath.com/news/patritumab-deruxtecan-with-without-letrozole-shows-comparable-efficacy-in-hr-her2 2024-12-11T21:33:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patritumab-deruxtecan-with-without-letrozole-shows-comparable-efficacy-in-hr-her2 2024-12-11T21:33:19+00:00 weekly 0.7 https://trial.medpath.com/news/ash-2024-discussions-shine-spotlight-on-advances-in-haemophilia-treatments 2024-12-11T21:22:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ash-2024-discussions-shine-spotlight-on-advances-in-haemophilia-treatments 2024-12-11T21:22:29+00:00 weekly 0.7 https://trial.medpath.com/news/anaptysbio-pulls-out-of-eczema-drug-race-after-phase-ii-flop-firstword-pharma 2024-12-11T21:13:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anaptysbio-pulls-out-of-eczema-drug-race-after-phase-ii-flop-firstword-pharma 2024-12-11T21:13:20+00:00 weekly 0.7 https://trial.medpath.com/news/fempulse-receives-fda-ide-approval-for-the-pivotal-clinical-trial-of-its-wearable-morningstar 2024-12-11T20:44:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fempulse-receives-fda-ide-approval-for-the-pivotal-clinical-trial-of-its-wearable-morningstar 2024-12-11T20:44:40+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-s-rsv-vaccines-run-into-safety-roadblock-biospace 2024-12-11T19:54:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-s-rsv-vaccines-run-into-safety-roadblock-biospace 2024-12-11T19:54:04+00:00 weekly 0.7 https://trial.medpath.com/news/weight-loss-jabs-like-ozempic-may-reduce-effectiveness-of-breast-cancer-treatments-study-finds 2024-12-11T19:50:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weight-loss-jabs-like-ozempic-may-reduce-effectiveness-of-breast-cancer-treatments-study-finds 2024-12-11T19:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-shr-a1811-demonstrates-efficacy-safety-in-her2-breast-cancer 2024-12-11T19:38:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-shr-a1811-demonstrates-efficacy-safety-in-her2-breast-cancer 2024-12-11T19:38:18+00:00 weekly 0.7 https://trial.medpath.com/news/anne-sophie-michallet-md-phd-on-mrd-guided-vs-standard-combination-therapy-for 2024-12-11T19:21:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anne-sophie-michallet-md-phd-on-mrd-guided-vs-standard-combination-therapy-for 2024-12-11T19:21:40+00:00 weekly 0.7 https://trial.medpath.com/news/t-dxd-improves-pfs-irrespective-of-time-to-progression-type-of-endocrine-resistance-onclive 2024-12-11T19:13:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/t-dxd-improves-pfs-irrespective-of-time-to-progression-type-of-endocrine-resistance-onclive 2024-12-11T19:13:48+00:00 weekly 0.7 https://trial.medpath.com/news/sound-pharma-gets-positive-results-from-meniere-s-disease-drug-clinical-trial 2024-12-11T19:05:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sound-pharma-gets-positive-results-from-meniere-s-disease-drug-clinical-trial 2024-12-11T19:05:26+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-ceo-to-present-at-oppenheimer-movers-in-rare-disease-summit-quantisnow 2024-12-11T18:23:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocugen-ceo-to-present-at-oppenheimer-movers-in-rare-disease-summit-quantisnow 2024-12-11T18:23:27+00:00 weekly 0.7 https://trial.medpath.com/news/cardiff-oncology-reports-promising-phase-2-trial-results-yahoo-finance 2024-12-11T18:20:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardiff-oncology-reports-promising-phase-2-trial-results-yahoo-finance 2024-12-11T18:20:20+00:00 weekly 0.7 https://trial.medpath.com/news/covid-19-vaccine-efficacy-reduced-with-immunosuppressive-antiviral-hbv-drug-use 2024-12-11T18:08:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/covid-19-vaccine-efficacy-reduced-with-immunosuppressive-antiviral-hbv-drug-use 2024-12-11T18:08:39+00:00 weekly 0.7 https://trial.medpath.com/news/cardiff-oncology-announces-positive-colorectal-data-and-40m-stock-oversubscription 2024-12-11T17:51:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardiff-oncology-announces-positive-colorectal-data-and-40m-stock-oversubscription 2024-12-11T17:51:20+00:00 weekly 0.7 https://trial.medpath.com/news/ready-set-food-and-obviohealth-complete-recruitment-for-infant-food-allergy-study 2024-12-11T17:50:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ready-set-food-and-obviohealth-complete-recruitment-for-infant-food-allergy-study 2024-12-11T17:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/anaptys-announces-phase-2b-trial-of-anb032-a-btla-agonist-did-not-meet-primary-or 2024-12-11T17:22:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anaptys-announces-phase-2b-trial-of-anb032-a-btla-agonist-did-not-meet-primary-or 2024-12-11T17:22:21+00:00 weekly 0.7 https://trial.medpath.com/news/enrollment-open-for-trial-testing-nkx019-cell-therapy-in-aav-anca-vasculitis-news 2024-12-11T17:16:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enrollment-open-for-trial-testing-nkx019-cell-therapy-in-aav-anca-vasculitis-news 2024-12-11T17:16:38+00:00 weekly 0.7 https://trial.medpath.com/news/caredx-partners-with-tc-biopharm-to-support-achieve-clinical-trial-using-allocell-biospace 2024-12-11T17:11:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/caredx-partners-with-tc-biopharm-to-support-achieve-clinical-trial-using-allocell-biospace 2024-12-11T17:11:49+00:00 weekly 0.7 https://trial.medpath.com/news/can-2409-improves-dfs-in-intermediate-high-risk-localized-prostate-cancer-onclive 2024-12-11T17:02:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-2409-improves-dfs-in-intermediate-high-risk-localized-prostate-cancer-onclive 2024-12-11T17:02:53+00:00 weekly 0.7 https://trial.medpath.com/news/brain-sensing-car-t-cells-enhance-brain-tumor-therapy-inside-precision-medicine 2024-12-11T17:02:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brain-sensing-car-t-cells-enhance-brain-tumor-therapy-inside-precision-medicine 2024-12-11T17:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/gc-biopharma-s-hunterase-icv-approved-in-russia-for-severe-hunter-syndrome 2024-12-11T17:01:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gc-biopharma-s-hunterase-icv-approved-in-russia-for-severe-hunter-syndrome 2024-12-11T17:01:11+00:00 weekly 0.7 https://trial.medpath.com/news/memed-s-sepsis-test-receives-fda-breakthrough-device-status 2024-12-11T16:51:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/memed-s-sepsis-test-receives-fda-breakthrough-device-status 2024-12-11T16:51:41+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-testing-sublingual-cladribine-planned-for-next-year 2024-12-11T16:46:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-testing-sublingual-cladribine-planned-for-next-year 2024-12-11T16:46:38+00:00 weekly 0.7 https://trial.medpath.com/news/astria-therapeutics-announces-positive-final-results-from-target-enrollment-in-the-alpha 2024-12-11T16:45:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astria-therapeutics-announces-positive-final-results-from-target-enrollment-in-the-alpha 2024-12-11T16:45:38+00:00 weekly 0.7 https://trial.medpath.com/news/q32-bio-battered-by-study-failure-of-immune-drug-biopharma-dive 2024-12-11T16:16:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/q32-bio-battered-by-study-failure-of-immune-drug-biopharma-dive 2024-12-11T16:16:52+00:00 weekly 0.7 https://trial.medpath.com/news/benevolentai-restructures-lilly-preps-15b-buyback-program-biopharma-dive 2024-12-11T16:16:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/benevolentai-restructures-lilly-preps-15b-buyback-program-biopharma-dive 2024-12-11T16:16:51+00:00 weekly 0.7 https://trial.medpath.com/news/gnt-pharma-reports-significant-improvements-in-stroke-patients-treated-with-its-pr-newswire 2024-12-11T16:16:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gnt-pharma-reports-significant-improvements-in-stroke-patients-treated-with-its-pr-newswire 2024-12-11T16:16:41+00:00 weekly 0.7 https://trial.medpath.com/news/visible-trial-advances-diversity-in-psoriasis-research 2024-12-11T16:05:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/visible-trial-advances-diversity-in-psoriasis-research 2024-12-11T16:05:40+00:00 weekly 0.7 https://trial.medpath.com/news/candel-therapeutics-stock-up-172-after-phase-iii-prostate-cancer-success 2024-12-11T15:50:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/candel-therapeutics-stock-up-172-after-phase-iii-prostate-cancer-success 2024-12-11T15:50:08+00:00 weekly 0.7 https://trial.medpath.com/news/indian-scientists-develop-novel-gene-therapy-treatment-for-haemophilia 2024-12-11T15:41:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/indian-scientists-develop-novel-gene-therapy-treatment-for-haemophilia 2024-12-11T15:41:00+00:00 weekly 0.7 https://trial.medpath.com/news/updated-hep-b-vaccine-more-effective-for-people-with-hiv-newsroom 2024-12-11T15:37:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/updated-hep-b-vaccine-more-effective-for-people-with-hiv-newsroom 2024-12-11T15:37:31+00:00 weekly 0.7 https://trial.medpath.com/news/lynparza-r-olaparib-demonstrated-clinically-meaningful-prolonged-survival-benefit-in 2024-12-11T15:36:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lynparza-r-olaparib-demonstrated-clinically-meaningful-prolonged-survival-benefit-in 2024-12-11T15:36:42+00:00 weekly 0.7 https://trial.medpath.com/news/rapidpulse-receives-fda-approval-to-begin-ide-study-in-ischemic-stroke-using-innovative 2024-12-11T15:36:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rapidpulse-receives-fda-approval-to-begin-ide-study-in-ischemic-stroke-using-innovative 2024-12-11T15:36:04+00:00 weekly 0.7 https://trial.medpath.com/news/lynparza-r-olaparib-demonstrated-clinically-meaningful-prolonged-survival-benefit-in 2024-12-11T15:27:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lynparza-r-olaparib-demonstrated-clinically-meaningful-prolonged-survival-benefit-in 2024-12-11T15:27:39+00:00 weekly 0.7 https://trial.medpath.com/news/gland-pharma-gets-us-fda-approval-for-vitamin-k-deficiency-injectable-cnbc-tv18 2024-12-11T15:24:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gland-pharma-gets-us-fda-approval-for-vitamin-k-deficiency-injectable-cnbc-tv18 2024-12-11T15:24:06+00:00 weekly 0.7 https://trial.medpath.com/news/neurosense-receives-positive-fda-feedback-on-phase-3-study-design-for-primec 2024-12-11T14:59:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurosense-receives-positive-fda-feedback-on-phase-3-study-design-for-primec 2024-12-11T14:59:06+00:00 weekly 0.7 https://trial.medpath.com/news/ash-2024-inmind-study-results-position-monjuvi-as-a-promising-therapy-for-r-r-follicular-lymphoma 2024-12-11T14:56:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ash-2024-inmind-study-results-position-monjuvi-as-a-promising-therapy-for-r-r-follicular-lymphoma 2024-12-11T14:56:25+00:00 weekly 0.7 https://trial.medpath.com/news/ash24-leukemia-drug-sequencing-sickle-cell-questions-and-a-new-kind-of-car-t 2024-12-11T14:44:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ash24-leukemia-drug-sequencing-sickle-cell-questions-and-a-new-kind-of-car-t 2024-12-11T14:44:10+00:00 weekly 0.7 https://trial.medpath.com/news/nature-biotechnology-generative-chemistry-enables-insilico-to-develop-gut-restricted 2024-12-11T14:30:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nature-biotechnology-generative-chemistry-enables-insilico-to-develop-gut-restricted 2024-12-11T14:30:46+00:00 weekly 0.7 https://trial.medpath.com/news/provectus-biopharmaceuticals-launches-visirose-provectus-s-globenewswire 2024-12-11T14:11:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/provectus-biopharmaceuticals-launches-visirose-provectus-s-globenewswire 2024-12-11T14:11:28+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-could-treat-alzheimer-s-disease-drug-discovery-news 2024-12-11T14:08:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-therapy-could-treat-alzheimer-s-disease-drug-discovery-news 2024-12-11T14:08:27+00:00 weekly 0.7 https://trial.medpath.com/news/transposon-presents-results-from-successful-phase-2-als-ftd-clinical-trial-aftd 2024-12-11T14:02:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/transposon-presents-results-from-successful-phase-2-als-ftd-clinical-trial-aftd 2024-12-11T14:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/60-degrees-pharma-expands-promising-babesiosis-treatment-trial-to-brigham-women-s-hospital 2024-12-11T13:59:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/60-degrees-pharma-expands-promising-babesiosis-treatment-trial-to-brigham-women-s-hospital 2024-12-11T13:59:37+00:00 weekly 0.7 https://trial.medpath.com/news/aprea-therapeutics-advances-novel-cancer-drug-trial-with-breakthrough-dosing-strategy 2024-12-11T13:37:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aprea-therapeutics-advances-novel-cancer-drug-trial-with-breakthrough-dosing-strategy 2024-12-11T13:37:58+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-s-annamycin-shows-breakthrough-results-against-drug-resistant-leukemia-in-key-study 2024-12-11T13:06:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moleculin-s-annamycin-shows-breakthrough-results-against-drug-resistant-leukemia-in-key-study 2024-12-11T13:06:15+00:00 weekly 0.7 https://trial.medpath.com/news/satellos-announces-first-participant-with-duchenne-muscular-dystrophy-dosed-in-the-biospace 2024-12-11T12:50:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/satellos-announces-first-participant-with-duchenne-muscular-dystrophy-dosed-in-the-biospace 2024-12-11T12:50:04+00:00 weekly 0.7 https://trial.medpath.com/news/adams-clinical-announces-expansion-into-inpatient-psychiatry-and-schizophrenia-morningstar 2024-12-11T12:48:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adams-clinical-announces-expansion-into-inpatient-psychiatry-and-schizophrenia-morningstar 2024-12-11T12:48:07+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-legend-shrug-off-carvykti-s-challengers-with-new-phase-iii-data-biospace 2024-12-11T12:46:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-legend-shrug-off-carvykti-s-challengers-with-new-phase-iii-data-biospace 2024-12-11T12:46:56+00:00 weekly 0.7 https://trial.medpath.com/news/reunion-neuroscience-presented-re104-phase-1-data-at-the-globenewswire 2024-12-11T12:44:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reunion-neuroscience-presented-re104-phase-1-data-at-the-globenewswire 2024-12-11T12:44:27+00:00 weekly 0.7 https://trial.medpath.com/news/review-confirms-clinical-safety-of-sandoz-denosumab-biosimilar-vs-originator 2024-12-11T12:08:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/review-confirms-clinical-safety-of-sandoz-denosumab-biosimilar-vs-originator 2024-12-11T12:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/pharming-announces-positive-topline-data-in-pediatric-clinical-trial-of-leniolisib 2024-12-11T12:02:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharming-announces-positive-topline-data-in-pediatric-clinical-trial-of-leniolisib 2024-12-11T12:02:52+00:00 weekly 0.7 https://trial.medpath.com/news/daiichi-sankyo-doses-first-subject-in-phase-iii-aml-therapy-trial 2024-12-11T11:57:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/daiichi-sankyo-doses-first-subject-in-phase-iii-aml-therapy-trial 2024-12-11T11:57:47+00:00 weekly 0.7 https://trial.medpath.com/news/seastar-medical-projects-multibillion-dollar-market-globenewswire 2024-12-11T11:56:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/seastar-medical-projects-multibillion-dollar-market-globenewswire 2024-12-11T11:56:35+00:00 weekly 0.7 https://trial.medpath.com/news/fcrn-inhibitor-market-size-target-population-competitive-globenewswire 2024-12-11T11:27:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fcrn-inhibitor-market-size-target-population-competitive-globenewswire 2024-12-11T11:27:02+00:00 weekly 0.7 https://trial.medpath.com/news/immunotech-biopharm-ltd-announces-car-t-19-injection-receives-breakthrough-therapy 2024-12-11T11:20:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotech-biopharm-ltd-announces-car-t-19-injection-receives-breakthrough-therapy 2024-12-11T11:20:33+00:00 weekly 0.7 https://trial.medpath.com/news/women-with-cancer-can-safely-use-rogaine-to-curb-hair-loss 2024-12-11T11:12:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/women-with-cancer-can-safely-use-rogaine-to-curb-hair-loss 2024-12-11T11:12:50+00:00 weekly 0.7 https://trial.medpath.com/news/removing-storing-patient-s-blood-before-liver-surgery-helps-avoid-transfusions 2024-12-11T11:12:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/removing-storing-patient-s-blood-before-liver-surgery-helps-avoid-transfusions 2024-12-11T11:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/repare-therapeutics-to-host-webcast-to-report-data-from-the-lunresertib-and-camonsertib 2024-12-11T11:04:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/repare-therapeutics-to-host-webcast-to-report-data-from-the-lunresertib-and-camonsertib 2024-12-11T11:04:41+00:00 weekly 0.7 https://trial.medpath.com/news/hunt-for-next-obesity-breakthrough-sends-biotech-stock-soaring-health-tech-world 2024-12-11T11:01:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hunt-for-next-obesity-breakthrough-sends-biotech-stock-soaring-health-tech-world 2024-12-11T11:01:32+00:00 weekly 0.7 https://trial.medpath.com/news/microbot-medical-r-announces-fda-submission-for-the-commercialization-of-the-liberty 2024-12-11T10:53:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/microbot-medical-r-announces-fda-submission-for-the-commercialization-of-the-liberty 2024-12-11T10:53:37+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-two-combination-vaccine-candidates-for-prevention-of-influenza-and-covid 2024-12-11T10:45:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-two-combination-vaccine-candidates-for-prevention-of-influenza-and-covid 2024-12-11T10:45:36+00:00 weekly 0.7 https://trial.medpath.com/news/ionctura-reaches-new-clinical-milestones-in-uveal-melanoma-pr-newswire 2024-12-11T10:43:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ionctura-reaches-new-clinical-milestones-in-uveal-melanoma-pr-newswire 2024-12-11T10:43:44+00:00 weekly 0.7 https://trial.medpath.com/news/will-eli-lilly-s-blockbuster-obesity-drug-be-available-in-india-by-2025-business-today 2024-12-11T10:41:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/will-eli-lilly-s-blockbuster-obesity-drug-be-available-in-india-by-2025-business-today 2024-12-11T10:41:54+00:00 weekly 0.7 https://trial.medpath.com/news/insilico-medicine-advances-with-generative-ai-in-drug-discovery 2024-12-11T09:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/insilico-medicine-advances-with-generative-ai-in-drug-discovery 2024-12-11T09:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/cyrus-biotechnology-advances-cyr212-for-chronic-autoimmune-diseases-with-improved-igg-depletion-profile 2024-12-11T09:07:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cyrus-biotechnology-advances-cyr212-for-chronic-autoimmune-diseases-with-improved-igg-depletion-profile 2024-12-11T09:07:32+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-liga-chem-bio-s-ind-for-novel-adc-cancer-therapy-komedidaskeom 2024-12-11T09:07:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-liga-chem-bio-s-ind-for-novel-adc-cancer-therapy-komedidaskeom 2024-12-11T09:07:09+00:00 weekly 0.7 https://trial.medpath.com/news/tasca-therapeutics-launches-with-52-million-series-a-financing-to-develop-small-biospace 2024-12-11T08:55:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tasca-therapeutics-launches-with-52-million-series-a-financing-to-develop-small-biospace 2024-12-11T08:55:43+00:00 weekly 0.7 https://trial.medpath.com/news/noema-pharma-ag-extends-series-b-financing-european-biotechnology-magazine 2024-12-11T08:38:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/noema-pharma-ag-extends-series-b-financing-european-biotechnology-magazine 2024-12-11T08:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/osf-partners-with-the-kevin-brown-strong-foundation-to-fight-glioblastoma-with-clinical-trials 2024-12-11T08:30:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/osf-partners-with-the-kevin-brown-strong-foundation-to-fight-glioblastoma-with-clinical-trials 2024-12-11T08:30:09+00:00 weekly 0.7 https://trial.medpath.com/news/strategic-dose-rounding-in-biologics-balancing-cost-savings-with-patient-safety 2024-12-11T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/strategic-dose-rounding-in-biologics-balancing-cost-savings-with-patient-safety 2024-12-11T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-cost-barriers-us-healthcare-faces-20-4-billion-annual-spending-challenge 2024-12-11T07:13:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-therapy-cost-barriers-us-healthcare-faces-20-4-billion-annual-spending-challenge 2024-12-11T07:13:18+00:00 weekly 0.7 https://trial.medpath.com/news/most-scd-patients-given-lyfgenia-in-trials-stay-free-of-voes-new-data 2024-12-11T06:12:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/most-scd-patients-given-lyfgenia-in-trials-stay-free-of-voes-new-data 2024-12-11T06:12:31+00:00 weekly 0.7 https://trial.medpath.com/news/news-researchers-launch-clinical-trial-testing-stellenbosch-university 2024-12-11T06:09:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/news-researchers-launch-clinical-trial-testing-stellenbosch-university 2024-12-11T06:09:19+00:00 weekly 0.7 https://trial.medpath.com/news/survey-reveals-top-challenges-for-biotechs-in-early-phase-clinical-trials 2024-12-11T05:23:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/survey-reveals-top-challenges-for-biotechs-in-early-phase-clinical-trials 2024-12-11T05:23:58+00:00 weekly 0.7 https://trial.medpath.com/news/gbm-organoids-models-patient-response-to-car-t-cell-therapy-in-real-time 2024-12-11T05:01:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gbm-organoids-models-patient-response-to-car-t-cell-therapy-in-real-time 2024-12-11T05:01:40+00:00 weekly 0.7 https://trial.medpath.com/news/new-biomarker-testing-protocol-could-shorten-antibiotic-treatment-for-sepsis-news-medical 2024-12-11T04:15:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-biomarker-testing-protocol-could-shorten-antibiotic-treatment-for-sepsis-news-medical 2024-12-11T04:15:27+00:00 weekly 0.7 https://trial.medpath.com/news/dr-wang-on-ziftomenib-plus-intensive-induction-in-newly-diagnosed-mutated-aml 2024-12-11T03:48:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-wang-on-ziftomenib-plus-intensive-induction-in-newly-diagnosed-mutated-aml 2024-12-11T03:48:24+00:00 weekly 0.7 https://trial.medpath.com/news/novel-drug-fails-for-two-rare-seizure-disorders-medpage-today 2024-12-11T03:26:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-drug-fails-for-two-rare-seizure-disorders-medpage-today 2024-12-11T03:26:59+00:00 weekly 0.7 https://trial.medpath.com/news/pilatus-biosciences-inc-secures-fda-orphan-drug-designation-for-plt012-pr-newswire 2024-12-11T03:13:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pilatus-biosciences-inc-secures-fda-orphan-drug-designation-for-plt012-pr-newswire 2024-12-11T03:13:38+00:00 weekly 0.7 https://trial.medpath.com/news/a-continued-evolution-psychiatric-times 2024-12-11T03:01:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-continued-evolution-psychiatric-times 2024-12-11T03:01:26+00:00 weekly 0.7 https://trial.medpath.com/news/november-s-fda-approvals-include-autolus-cd19-car-t-biocentury 2024-12-11T02:17:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/november-s-fda-approvals-include-autolus-cd19-car-t-biocentury 2024-12-11T02:17:17+00:00 weekly 0.7 https://trial.medpath.com/news/glofitamab-plus-polatuzumab-shows-durable-results-in-r-r-lbcl-targeted-oncology 2024-12-11T01:32:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glofitamab-plus-polatuzumab-shows-durable-results-in-r-r-lbcl-targeted-oncology 2024-12-11T01:32:52+00:00 weekly 0.7 https://trial.medpath.com/news/bringing-it-all-back-home-reshaping-ophthalmology-s-clinic-with-home-oct-hcplive 2024-12-11T01:06:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bringing-it-all-back-home-reshaping-ophthalmology-s-clinic-with-home-oct-hcplive 2024-12-11T01:06:26+00:00 weekly 0.7 https://trial.medpath.com/news/kira-pharmaceuticals-presents-updated-data-of-phase-2-study-of-kp104-in-paroxysmal 2024-12-11T01:02:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kira-pharmaceuticals-presents-updated-data-of-phase-2-study-of-kp104-in-paroxysmal 2024-12-11T01:02:17+00:00 weekly 0.7 https://trial.medpath.com/news/tyra-biosciences-stock-target-adjusted-following-clinical-data-review 2024-12-11T00:50:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tyra-biosciences-stock-target-adjusted-following-clinical-data-review 2024-12-11T00:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/visirose-unveils-breakthrough-therapy-for-eye-infections-mirage-news 2024-12-11T00:44:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/visirose-unveils-breakthrough-therapy-for-eye-infections-mirage-news 2024-12-11T00:44:58+00:00 weekly 0.7 https://trial.medpath.com/news/psyence-biomed-executes-binding-agreements-with-optimi-health-corp-stock-titan 2024-12-11T00:39:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psyence-biomed-executes-binding-agreements-with-optimi-health-corp-stock-titan 2024-12-11T00:39:10+00:00 weekly 0.7 https://trial.medpath.com/news/iv-form-of-nac-receives-fda-snda-to-prevent-lessen-liver-injury-after-ingesting-toxic 2024-12-11T00:23:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iv-form-of-nac-receives-fda-snda-to-prevent-lessen-liver-injury-after-ingesting-toxic 2024-12-11T00:23:58+00:00 weekly 0.7 https://trial.medpath.com/news/alternating-modified-capox-capiri-plus-bevacizumab-in-untreated-unresectable-metastatic 2024-12-11T00:02:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alternating-modified-capox-capiri-plus-bevacizumab-in-untreated-unresectable-metastatic 2024-12-11T00:02:18+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-price-target-lowered-to-13-from-15-at-wells-fargo-tipranks-com 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acelyrin-price-target-lowered-to-13-from-15-at-wells-fargo-tipranks-com 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/prophylactic-tocilizumab-may-enhance-access-to-bispecific-therapies-for-multiple-myeloma 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prophylactic-tocilizumab-may-enhance-access-to-bispecific-therapies-for-multiple-myeloma 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/accent-therapeutics-doses-first-patient-in-phase-1-2-trial-of-atx-559-and-announces-cso-transition 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/accent-therapeutics-doses-first-patient-in-phase-1-2-trial-of-atx-559-and-announces-cso-transition 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/teclistamab-shows-promising-results-in-chinese-patients-with-relapsed-refractory-multiple-myeloma 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/teclistamab-shows-promising-results-in-chinese-patients-with-relapsed-refractory-multiple-myeloma 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/point72-asset-management-l-p-has-1-23-million-position-in-acelyrin-inc-nasdaq-slrn 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/point72-asset-management-l-p-has-1-23-million-position-in-acelyrin-inc-nasdaq-slrn 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novotech-selected-for-new-covid-19-clinical-trial-in-asia-pacific 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novotech-selected-for-new-covid-19-clinical-trial-in-asia-pacific 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/belhaven-biopharma-to-present-nasdepi-r-data-at-ddl-2024 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/belhaven-biopharma-to-present-nasdepi-r-data-at-ddl-2024 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/the-future-of-factor-xi-inhibitors-in-atrial-fibrillation-treatment 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-future-of-factor-xi-inhibitors-in-atrial-fibrillation-treatment 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-clinical-trial-of-etns-for-pediatric-adhd-to-commence-in-denmark 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-clinical-trial-of-etns-for-pediatric-adhd-to-commence-in-denmark 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/prospective-clinical-utility-study-of-lucid-diagnostics-esoguard-r-esophageal-dna-test-accepted-for-peer-reviewed-publication 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prospective-clinical-utility-study-of-lucid-diagnostics-esoguard-r-esophageal-dna-test-accepted-for-peer-reviewed-publication 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/protaryx-medical-completes-first-in-human-trial-of-transseptal-puncture-device 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protaryx-medical-completes-first-in-human-trial-of-transseptal-puncture-device 2024-12-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-announces-first-patient-in-for-phase-1-clinical-trial-evaluating-ide161-in-pr-newswire 2024-12-10T23:01:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ideaya-announces-first-patient-in-for-phase-1-clinical-trial-evaluating-ide161-in-pr-newswire 2024-12-10T23:01:04+00:00 weekly 0.7 https://trial.medpath.com/news/mirum-pharmaceuticals-advances-in-liver-disease-treatments 2024-12-10T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mirum-pharmaceuticals-advances-in-liver-disease-treatments 2024-12-10T23:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/therapy-for-genetic-epilepsy-in-children-showing-promise-vumc-news 2024-12-10T22:52:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/therapy-for-genetic-epilepsy-in-children-showing-promise-vumc-news 2024-12-10T22:52:50+00:00 weekly 0.7 https://trial.medpath.com/news/positive-new-data-and-strong-recruitment-in-pancreatic-cancer-trial-biomelbourne-network 2024-12-10T22:22:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-new-data-and-strong-recruitment-in-pancreatic-cancer-trial-biomelbourne-network 2024-12-10T22:22:21+00:00 weekly 0.7 https://trial.medpath.com/news/ignite-biomedical-achieves-key-milestone-in-precision-medicine-with-successful-analytical 2024-12-10T22:09:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ignite-biomedical-achieves-key-milestone-in-precision-medicine-with-successful-analytical 2024-12-10T22:09:27+00:00 weekly 0.7 https://trial.medpath.com/news/cellectar-biosciences-provides-strategic-update-on-clinical-development-pipeline 2024-12-10T22:03:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cellectar-biosciences-provides-strategic-update-on-clinical-development-pipeline 2024-12-10T22:03:59+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-inc-announces-topline-results-from-phase-2b-3-globenewswire 2024-12-10T21:46:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acelyrin-inc-announces-topline-results-from-phase-2b-3-globenewswire 2024-12-10T21:46:29+00:00 weekly 0.7 https://trial.medpath.com/news/therapeutic-clinical-trial-eligibility-and-enrollment-among-women-with-breast-cancer 2024-12-10T21:12:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/therapeutic-clinical-trial-eligibility-and-enrollment-among-women-with-breast-cancer 2024-12-10T21:12:13+00:00 weekly 0.7 https://trial.medpath.com/news/moberg-pharma-reports-topline-data-in-the-north-american-phase-3-study-and-will-regain 2024-12-10T20:49:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moberg-pharma-reports-topline-data-in-the-north-american-phase-3-study-and-will-regain 2024-12-10T20:49:34+00:00 weekly 0.7 https://trial.medpath.com/news/axi-cel-demonstrates-long-term-efficacy-in-relapsed-refractory-follicular-lymphoma-and-marginal-zone-lymphoma 2024-12-10T20:33:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/axi-cel-demonstrates-long-term-efficacy-in-relapsed-refractory-follicular-lymphoma-and-marginal-zone-lymphoma 2024-12-10T20:33:10+00:00 weekly 0.7 https://trial.medpath.com/news/md-anderson-and-ammax-bio-announce-agreements-to-advance-development-of-amb-066 2024-12-10T20:18:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/md-anderson-and-ammax-bio-announce-agreements-to-advance-development-of-amb-066 2024-12-10T20:18:39+00:00 weekly 0.7 https://trial.medpath.com/news/nih-study-finds-tecovirimat-was-safe-but-did-not-improve-mpox-resolution-or-pain 2024-12-10T20:16:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-study-finds-tecovirimat-was-safe-but-did-not-improve-mpox-resolution-or-pain 2024-12-10T20:16:23+00:00 weekly 0.7 https://trial.medpath.com/news/hope-for-parkinson-s-disease-symptoms-is-found-in-late-stage-drug-study-fortune 2024-12-10T20:13:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hope-for-parkinson-s-disease-symptoms-is-found-in-late-stage-drug-study-fortune 2024-12-10T20:13:29+00:00 weekly 0.7 https://trial.medpath.com/news/pirtobrutinib-triplet-improves-mrd-outcomes-in-cll-cancer-network 2024-12-10T20:03:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pirtobrutinib-triplet-improves-mrd-outcomes-in-cll-cancer-network 2024-12-10T20:03:10+00:00 weekly 0.7 https://trial.medpath.com/news/astria-therapeutics-announces-fda-clearance-of-ind-application-for-star-0310-a-biospace 2024-12-10T19:41:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astria-therapeutics-announces-fda-clearance-of-ind-application-for-star-0310-a-biospace 2024-12-10T19:41:48+00:00 weekly 0.7 https://trial.medpath.com/news/revolutionary-cancer-drug-could-remove-side-effects-from-radiation-treatments-study-finds 2024-12-10T19:40:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/revolutionary-cancer-drug-could-remove-side-effects-from-radiation-treatments-study-finds 2024-12-10T19:40:38+00:00 weekly 0.7 https://trial.medpath.com/news/lisata-therapeutics-announces-completion-of-enrollment-in-the-cendifox-trial 2024-12-10T19:39:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lisata-therapeutics-announces-completion-of-enrollment-in-the-cendifox-trial 2024-12-10T19:39:48+00:00 weekly 0.7 https://trial.medpath.com/news/harnessing-ai-for-smarter-health-policy-research-school-of-public-health-brown-university 2024-12-10T19:19:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/harnessing-ai-for-smarter-health-policy-research-school-of-public-health-brown-university 2024-12-10T19:19:49+00:00 weekly 0.7 https://trial.medpath.com/news/cervomed-announces-topline-data-from-rewind-lb-phase-2b-clinical-trial-in-patients-with 2024-12-10T19:12:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cervomed-announces-topline-data-from-rewind-lb-phase-2b-clinical-trial-in-patients-with 2024-12-10T19:12:07+00:00 weekly 0.7 https://trial.medpath.com/news/ash-2024-regeneron-s-ordspono-faces-challenges-but-positive-results-signal-hope 2024-12-10T19:11:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ash-2024-regeneron-s-ordspono-faces-challenges-but-positive-results-signal-hope 2024-12-10T19:11:41+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-to-test-obesity-medications-as-treatments-for-alcohol-and-drug-addiction-stat-news 2024-12-10T19:05:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-to-test-obesity-medications-as-treatments-for-alcohol-and-drug-addiction-stat-news 2024-12-10T19:05:14+00:00 weekly 0.7 https://trial.medpath.com/news/alveron-pharma-closes-eur5-million-seed-extension-financing-to-accelerate-breakthrough-ich-therapy 2024-12-10T18:50:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alveron-pharma-closes-eur5-million-seed-extension-financing-to-accelerate-breakthrough-ich-therapy 2024-12-10T18:50:41+00:00 weekly 0.7 https://trial.medpath.com/news/geron-announces-new-imerge-analyses-presented-at-ash-suggesting-clinical-activity-of 2024-12-10T18:41:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/geron-announces-new-imerge-analyses-presented-at-ash-suggesting-clinical-activity-of 2024-12-10T18:41:35+00:00 weekly 0.7 https://trial.medpath.com/news/arvinas-pfizer-partner-cancer-drug-trial-shows-63-clinical-benefit-in-breast-cancer-patients 2024-12-10T18:31:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arvinas-pfizer-partner-cancer-drug-trial-shows-63-clinical-benefit-in-breast-cancer-patients 2024-12-10T18:31:47+00:00 weekly 0.7 https://trial.medpath.com/news/btk-degrader-bgb-16673-shows-promise-in-r-r-wm-and-cll-sll-cancer-network 2024-12-10T18:28:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/btk-degrader-bgb-16673-shows-promise-in-r-r-wm-and-cll-sll-cancer-network 2024-12-10T18:28:23+00:00 weekly 0.7 https://trial.medpath.com/news/new-strategy-for-vivoryon-as-second-failed-alzheimer-s-trial-shows-kidney-promise 2024-12-10T18:15:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-strategy-for-vivoryon-as-second-failed-alzheimer-s-trial-shows-kidney-promise 2024-12-10T18:15:47+00:00 weekly 0.7 https://trial.medpath.com/news/carvykti-significantly-boosts-survival-mrd-negativity-in-relapsed-multiple-myeloma 2024-12-10T17:26:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/carvykti-significantly-boosts-survival-mrd-negativity-in-relapsed-multiple-myeloma 2024-12-10T17:26:52+00:00 weekly 0.7 https://trial.medpath.com/news/merus-mrus-fda-approval-and-speculative-future-in-cancer-therapy-yahoo-finance 2024-12-10T17:13:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merus-mrus-fda-approval-and-speculative-future-in-cancer-therapy-yahoo-finance 2024-12-10T17:13:40+00:00 weekly 0.7 https://trial.medpath.com/news/ramose-phase-ii-trial-finds-promising-results-for-osimertinib-and-ramucirumab-in-non-small 2024-12-10T16:14:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ramose-phase-ii-trial-finds-promising-results-for-osimertinib-and-ramucirumab-in-non-small 2024-12-10T16:14:47+00:00 weekly 0.7 https://trial.medpath.com/news/humanetics-secures-additional-funding-to-advance-development-of-its-drug-to-prevent 2024-12-10T15:55:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/humanetics-secures-additional-funding-to-advance-development-of-its-drug-to-prevent 2024-12-10T15:55:19+00:00 weekly 0.7 https://trial.medpath.com/news/pafolacianine-shows-no-serious-adverse-effects-in-lung-cancer-surgery 2024-12-10T15:26:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pafolacianine-shows-no-serious-adverse-effects-in-lung-cancer-surgery 2024-12-10T15:26:04+00:00 weekly 0.7 https://trial.medpath.com/news/uk-clinical-trials-performance-improves-but-remains-in-intensive-care 2024-12-10T15:09:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-clinical-trials-performance-improves-but-remains-in-intensive-care 2024-12-10T15:09:49+00:00 weekly 0.7 https://trial.medpath.com/news/why-is-cancer-focused-chimerix-stock-trading-higher-on-tuesday-yahoo-finance 2024-12-10T14:50:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-is-cancer-focused-chimerix-stock-trading-higher-on-tuesday-yahoo-finance 2024-12-10T14:50:08+00:00 weekly 0.7 https://trial.medpath.com/news/the-start-center-for-cancer-research-expands-its-capabilities-to-support-early-phase 2024-12-10T14:44:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-start-center-for-cancer-research-expands-its-capabilities-to-support-early-phase 2024-12-10T14:44:29+00:00 weekly 0.7 https://trial.medpath.com/news/genmab-delivers-promising-data-from-cancer-drug-in-two-new-clinical-trials-medwatch 2024-12-10T14:25:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genmab-delivers-promising-data-from-cancer-drug-in-two-new-clinical-trials-medwatch 2024-12-10T14:25:38+00:00 weekly 0.7 https://trial.medpath.com/news/uniqure-gets-fda-ok-to-seek-accelerated-approval-stat-news 2024-12-10T14:20:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uniqure-gets-fda-ok-to-seek-accelerated-approval-stat-news 2024-12-10T14:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/atossa-therapeutics-to-present-pharmacokinetic-and-globenewswire 2024-12-10T14:10:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atossa-therapeutics-to-present-pharmacokinetic-and-globenewswire 2024-12-10T14:10:43+00:00 weekly 0.7 https://trial.medpath.com/news/theradaptive-obtains-fda-ide-approval-to-study-osteoadapttm-sp-in-additional-spinal 2024-12-10T14:04:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/theradaptive-obtains-fda-ide-approval-to-study-osteoadapttm-sp-in-additional-spinal 2024-12-10T14:04:16+00:00 weekly 0.7 https://trial.medpath.com/news/thiogenesis-announces-presentation-on-umdf-webcast-featuring-clinical-trials-in 2024-12-10T14:03:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/thiogenesis-announces-presentation-on-umdf-webcast-featuring-clinical-trials-in 2024-12-10T14:03:56+00:00 weekly 0.7 https://trial.medpath.com/news/curis-reports-promising-aml-study-results-by-investing-com 2024-12-10T13:46:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/curis-reports-promising-aml-study-results-by-investing-com 2024-12-10T13:46:13+00:00 weekly 0.7 https://trial.medpath.com/news/sirus-therapeutics-announces-positive-signals-from-phase-i-sirna-trial 2024-12-10T13:43:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sirus-therapeutics-announces-positive-signals-from-phase-i-sirna-trial 2024-12-10T13:43:46+00:00 weekly 0.7 https://trial.medpath.com/news/heart-specialists-praise-health-canada-approval-of-weight-loss-drug-wegovy-cp24 2024-12-10T13:41:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/heart-specialists-praise-health-canada-approval-of-weight-loss-drug-wegovy-cp24 2024-12-10T13:41:18+00:00 weekly 0.7 https://trial.medpath.com/news/sellas-life-sciences-triggers-interim-analysis-in-phase-3-regal-trial-of-gps-in-acute 2024-12-10T13:39:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sellas-life-sciences-triggers-interim-analysis-in-phase-3-regal-trial-of-gps-in-acute 2024-12-10T13:39:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-opens-accelerated-approval-path-for-clene-s-breakthrough-als-treatment-after-78 2024-12-10T13:32:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-opens-accelerated-approval-path-for-clene-s-breakthrough-als-treatment-after-78 2024-12-10T13:32:28+00:00 weekly 0.7 https://trial.medpath.com/news/curocell-s-car-t-therapy-picked-as-2nd-drug-for-expediated-approval-and-market-launch 2024-12-10T13:24:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/curocell-s-car-t-therapy-picked-as-2nd-drug-for-expediated-approval-and-market-launch 2024-12-10T13:24:10+00:00 weekly 0.7 https://trial.medpath.com/news/global-biosimilars-market-set-to-triple-to-114-billion-by-2031-driven-by-patent-expirations-and-cost-advantages 2024-12-10T13:23:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-biosimilars-market-set-to-triple-to-114-billion-by-2031-driven-by-patent-expirations-and-cost-advantages 2024-12-10T13:23:20+00:00 weekly 0.7 https://trial.medpath.com/news/sutro-biopharma-announces-selected-dose-for-luvelta-and-globenewswire 2024-12-10T13:11:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sutro-biopharma-announces-selected-dose-for-luvelta-and-globenewswire 2024-12-10T13:11:34+00:00 weekly 0.7 https://trial.medpath.com/news/renovorx-ceo-to-host-investor-fireside-chat-on-tuesday-december-17th-at-4-30-p-m-et 2024-12-10T13:10:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/renovorx-ceo-to-host-investor-fireside-chat-on-tuesday-december-17th-at-4-30-p-m-et 2024-12-10T13:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/onkure-announces-encouraging-preliminary-safety-and-pharmacokinetic-data-from-pikture-01-trial-of-oki-219 2024-12-10T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/onkure-announces-encouraging-preliminary-safety-and-pharmacokinetic-data-from-pikture-01-trial-of-oki-219 2024-12-10T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/quantum-biopharma-progresses-with-drug-trial-dosing-investing-com 2024-12-10T12:46:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quantum-biopharma-progresses-with-drug-trial-dosing-investing-com 2024-12-10T12:46:43+00:00 weekly 0.7 https://trial.medpath.com/news/lyell-immunopharma-announces-promising-initial-clinical-data-for-impt-314-in-treatment 2024-12-10T12:32:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lyell-immunopharma-announces-promising-initial-clinical-data-for-impt-314-in-treatment 2024-12-10T12:32:44+00:00 weekly 0.7 https://trial.medpath.com/news/uniqure-announces-alignment-with-fda-on-key-elements-of-accelerated-approval-pathway 2024-12-10T12:13:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uniqure-announces-alignment-with-fda-on-key-elements-of-accelerated-approval-pathway 2024-12-10T12:13:30+00:00 weekly 0.7 https://trial.medpath.com/news/scilex-forms-major-joint-venture-to-develop-novel-obesity-alzheimer-s-drug-after 2024-12-10T12:06:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scilex-forms-major-joint-venture-to-develop-novel-obesity-alzheimer-s-drug-after 2024-12-10T12:06:36+00:00 weekly 0.7 https://trial.medpath.com/news/merakris-therapeutics-announces-open-enrollment-for-phase-ii-clinical-trial-of-financial-post 2024-12-10T11:34:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merakris-therapeutics-announces-open-enrollment-for-phase-ii-clinical-trial-of-financial-post 2024-12-10T11:34:24+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-meds-may-lower-clot-risk-in-people-with-diabetes 2024-12-10T11:05:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glp-1-meds-may-lower-clot-risk-in-people-with-diabetes 2024-12-10T11:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/iaso-bio-s-car-t-therapy-shows-sustained-efficacy-in-multiple-myeloma-patients-with-renal-impairment 2024-12-10T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iaso-bio-s-car-t-therapy-shows-sustained-efficacy-in-multiple-myeloma-patients-with-renal-impairment 2024-12-10T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/hvivo-plc-aim-hvo-ps11-5m-rsv-contract-and-notice-of-trading-update-share-talk 2024-12-10T09:04:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hvivo-plc-aim-hvo-ps11-5m-rsv-contract-and-notice-of-trading-update-share-talk 2024-12-10T09:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/olverembatinib-shows-promise-as-second-line-therapy-for-non-t315i-mutant-cp-cml 2024-12-10T08:31:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/olverembatinib-shows-promise-as-second-line-therapy-for-non-t315i-mutant-cp-cml 2024-12-10T08:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/ixico-lands-ps500k-phase-ii-huntington-s-contract-aim-ixi-otc-phyof-proactive-investors 2024-12-10T08:12:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ixico-lands-ps500k-phase-ii-huntington-s-contract-aim-ixi-otc-phyof-proactive-investors 2024-12-10T08:12:20+00:00 weekly 0.7 https://trial.medpath.com/news/santhera-receives-positive-recommendation-from-nice-for-agamree-r-vamorolone-as 2024-12-10T06:11:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/santhera-receives-positive-recommendation-from-nice-for-agamree-r-vamorolone-as 2024-12-10T06:11:28+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-s-tavapadon-shows-promise-in-phase-3-parkinson-s-disease-trial 2024-12-10T06:06:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-s-tavapadon-shows-promise-in-phase-3-parkinson-s-disease-trial 2024-12-10T06:06:25+00:00 weekly 0.7 https://trial.medpath.com/news/new-and-updated-data-for-roche-s-fixed-duration-columvi-and-globenewswire 2024-12-10T06:02:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-and-updated-data-for-roche-s-fixed-duration-columvi-and-globenewswire 2024-12-10T06:02:08+00:00 weekly 0.7 https://trial.medpath.com/news/experts-challenge-os-as-gold-standard-endpoint-in-cancer-drug-trials-pfs-gains-clinical-relevance 2024-12-10T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-challenge-os-as-gold-standard-endpoint-in-cancer-drug-trials-pfs-gains-clinical-relevance 2024-12-10T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/comprehensive-management-guidelines-released-for-talquetamab-treatment-in-multiple-myeloma-patients 2024-12-10T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comprehensive-management-guidelines-released-for-talquetamab-treatment-in-multiple-myeloma-patients 2024-12-10T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eye-disease-focused-kodiak-sciences-is-a-promising-turnaround-story-for-2025-benzinga 2024-12-10T05:36:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eye-disease-focused-kodiak-sciences-is-a-promising-turnaround-story-for-2025-benzinga 2024-12-10T05:36:22+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approved-vowst-offers-novel-treatment-approach-for-recurrent-c-difficile-infections 2024-12-10T05:05:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approved-vowst-offers-novel-treatment-approach-for-recurrent-c-difficile-infections 2024-12-10T05:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/immune-onc-therapeutics-presents-updated-data-from-phase-1b-study-of-io-202-biospace 2024-12-10T05:02:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immune-onc-therapeutics-presents-updated-data-from-phase-1b-study-of-io-202-biospace 2024-12-10T05:02:14+00:00 weekly 0.7 https://trial.medpath.com/news/lyell-presents-positive-initial-clinical-data-from-the-phase-1-2-clinical-trial-of-impt-314-for 2024-12-10T05:02:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lyell-presents-positive-initial-clinical-data-from-the-phase-1-2-clinical-trial-of-impt-314-for 2024-12-10T05:02:14+00:00 weekly 0.7 https://trial.medpath.com/news/glenmark-s-blood-cancer-drug-isb-2001-shows-83-response-rate-in-phase-1-multiple-myeloma-trial 2024-12-10T04:29:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glenmark-s-blood-cancer-drug-isb-2001-shows-83-response-rate-in-phase-1-multiple-myeloma-trial 2024-12-10T04:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/immutep-initiates-phase-iii-trial-for-lung-cancer-markets-insider 2024-12-10T03:49:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immutep-initiates-phase-iii-trial-for-lung-cancer-markets-insider 2024-12-10T03:49:41+00:00 weekly 0.7 https://trial.medpath.com/news/pediatric-cancer-clinical-trial-research-should-include-social-determinants-of-health 2024-12-10T02:50:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pediatric-cancer-clinical-trial-research-should-include-social-determinants-of-health 2024-12-10T02:50:02+00:00 weekly 0.7 https://trial.medpath.com/news/ghana-becomes-first-river-blindness-endemic-country-to-approve-moxidectin-biomelbourne-network 2024-12-10T02:39:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ghana-becomes-first-river-blindness-endemic-country-to-approve-moxidectin-biomelbourne-network 2024-12-10T02:39:40+00:00 weekly 0.7 https://trial.medpath.com/news/zealand-pharma-announces-first-participant-enrolled-in-phase-2b-zupreme-1-trial-of-petrelintide-in-people-with-overweight-or-obesity 2024-12-10T02:12:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zealand-pharma-announces-first-participant-enrolled-in-phase-2b-zupreme-1-trial-of-petrelintide-in-people-with-overweight-or-obesity 2024-12-10T02:12:56+00:00 weekly 0.7 https://trial.medpath.com/news/beigene-s-brukinsa-shows-breakthrough-71-risk-reduction-in-5-year-cll-study-at-ash 2024-12-10T01:31:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/beigene-s-brukinsa-shows-breakthrough-71-risk-reduction-in-5-year-cll-study-at-ash 2024-12-10T01:31:17+00:00 weekly 0.7 https://trial.medpath.com/news/comprehensive-treatment-options-expand-for-non-familial-hypercholesterolemia-management 2024-12-10T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comprehensive-treatment-options-expand-for-non-familial-hypercholesterolemia-management 2024-12-10T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-white-paper-highlights-critical-success-factors-for-modern-pharmaceutical-product-launches 2024-12-10T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-white-paper-highlights-critical-success-factors-for-modern-pharmaceutical-product-launches 2024-12-10T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kites-yescarta-only-car-t-cell-therapy-to-show-durable-response-and-long-gilead-sciences 2024-12-10T00:34:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kites-yescarta-only-car-t-cell-therapy-to-show-durable-response-and-long-gilead-sciences 2024-12-10T00:34:16+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-gene-therapy-offers-new-hope-to-child-with-muscular-dystrophy-the-tennessean 2024-12-10T00:18:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-gene-therapy-offers-new-hope-to-child-with-muscular-dystrophy-the-tennessean 2024-12-10T00:18:40+00:00 weekly 0.7 https://trial.medpath.com/news/positive-phase-3-trial-results-for-rilzabrutinib-support-buy-rating 2024-12-10T00:07:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-phase-3-trial-results-for-rilzabrutinib-support-buy-rating 2024-12-10T00:07:00+00:00 weekly 0.7 https://trial.medpath.com/news/tempus-announces-four-abstracts-accepted-for-presentation-at-the-2024-san-antonio-breast-cancer-symposium 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tempus-announces-four-abstracts-accepted-for-presentation-at-the-2024-san-antonio-breast-cancer-symposium 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/major-milestone-for-uq-spin-out-s-promising-mnd-drug 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/major-milestone-for-uq-spin-out-s-promising-mnd-drug 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/correcting-and-replacing-maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/correcting-and-replacing-maat-pharma-presented-positive-updated-data-on-maat013-in-the-early-access-program-at-ash-2024-annual-meeting 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/year-in-review-chronic-lymphocytic-leukemia 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/year-in-review-chronic-lymphocytic-leukemia 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/syntara-announces-positive-interim-data-in-phase-2-study-of-snt-5505-in-myelofibrosis 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syntara-announces-positive-interim-data-in-phase-2-study-of-snt-5505-in-myelofibrosis 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tourmaline-bio-highlights-cardiovascular-inflammation-focus-and-announces-key-clinical-and-strategic-updates-at-investor-day 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tourmaline-bio-highlights-cardiovascular-inflammation-focus-and-announces-key-clinical-and-strategic-updates-at-investor-day 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/what-s-going-on-with-recursion-pharmaceuticals-stock 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-s-going-on-with-recursion-pharmaceuticals-stock 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/with-promising-early-data-in-triple-negative-breast-cancer-a-new-bispecific-heats-up 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/with-promising-early-data-in-triple-negative-breast-cancer-a-new-bispecific-heats-up 2024-12-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/maia-biotechnology-secures-950k-private-placement-to-advance-thio-clinical-trials 2024-12-09T23:06:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maia-biotechnology-secures-950k-private-placement-to-advance-thio-clinical-trials 2024-12-09T23:06:41+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-s-odronextamab-shows-remarkable-100-response-rate-in-lymphoma 2024-12-09T22:56:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regeneron-s-odronextamab-shows-remarkable-100-response-rate-in-lymphoma 2024-12-09T22:56:01+00:00 weekly 0.7 https://trial.medpath.com/news/longest-follow-up-data-reported-for-kites-tecartus-car-t-cell-therapy-at-ash-2024 2024-12-09T22:47:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/longest-follow-up-data-reported-for-kites-tecartus-car-t-cell-therapy-at-ash-2024 2024-12-09T22:47:26+00:00 weekly 0.7 https://trial.medpath.com/news/ash-2024-astrazeneca-set-to-take-a-bite-out-of-follicular-lymphoma-market 2024-12-09T22:40:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ash-2024-astrazeneca-set-to-take-a-bite-out-of-follicular-lymphoma-market 2024-12-09T22:40:19+00:00 weekly 0.7 https://trial.medpath.com/news/spotlight-glow-trials-lead-to-fda-approval-of-zolbetuximab-clzb-with-chemotherapy 2024-12-09T22:15:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spotlight-glow-trials-lead-to-fda-approval-of-zolbetuximab-clzb-with-chemotherapy 2024-12-09T22:15:51+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-rezdiffra-first-fatty-liver-disease-drug-explained-woman-s-world 2024-12-09T21:49:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-rezdiffra-first-fatty-liver-disease-drug-explained-woman-s-world 2024-12-09T21:49:37+00:00 weekly 0.7 https://trial.medpath.com/news/sellas-stock-announces-positive-data-from-phase-2-trial-of-sls009-rttnews 2024-12-09T21:36:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sellas-stock-announces-positive-data-from-phase-2-trial-of-sls009-rttnews 2024-12-09T21:36:35+00:00 weekly 0.7 https://trial.medpath.com/news/theratechnologies-initial-efficacy-data-from-ovarian-cancer-drug-trial-shows-encouraging-results 2024-12-09T21:36:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/theratechnologies-initial-efficacy-data-from-ovarian-cancer-drug-trial-shows-encouraging-results 2024-12-09T21:36:16+00:00 weekly 0.7 https://trial.medpath.com/news/krystal-biotech-provides-update-on-ema-s-ongoing-regulatory-review-of-b-vec-for 2024-12-09T21:20:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/krystal-biotech-provides-update-on-ema-s-ongoing-regulatory-review-of-b-vec-for 2024-12-09T21:20:32+00:00 weekly 0.7 https://trial.medpath.com/news/protagonist-reports-final-results-from-rusfertide-phase-2-revive-study-showing-durable 2024-12-09T21:19:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protagonist-reports-final-results-from-rusfertide-phase-2-revive-study-showing-durable 2024-12-09T21:19:20+00:00 weekly 0.7 https://trial.medpath.com/news/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-globenewswire 2024-12-09T21:10:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/relay-therapeutics-to-present-updated-clinical-data-on-rly-2608-in-hr-her2-globenewswire 2024-12-09T21:10:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-acetadote-r-snda-stock-titan 2024-12-09T21:10:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-acetadote-r-snda-stock-titan 2024-12-09T21:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/survey-titrating-trofinetide-improves-tolerability-among-rett-syndrome-patients 2024-12-09T20:58:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/survey-titrating-trofinetide-improves-tolerability-among-rett-syndrome-patients 2024-12-09T20:58:32+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-review-donanemab-azbt-approved-for-early-symptomatic-alzheimer-disease 2024-12-09T20:54:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-drug-review-donanemab-azbt-approved-for-early-symptomatic-alzheimer-disease 2024-12-09T20:54:29+00:00 weekly 0.7 https://trial.medpath.com/news/venetoclax-cladribine-improves-response-rates-in-aml-mds-cohorts-cancer-network 2024-12-09T20:39:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/venetoclax-cladribine-improves-response-rates-in-aml-mds-cohorts-cancer-network 2024-12-09T20:39:11+00:00 weekly 0.7 https://trial.medpath.com/news/insights-on-ucb-s-commitment-to-advancing-rare-epilepsy-care-neurologylive 2024-12-09T20:16:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/insights-on-ucb-s-commitment-to-advancing-rare-epilepsy-care-neurologylive 2024-12-09T20:16:43+00:00 weekly 0.7 https://trial.medpath.com/news/beacon-therapeutics-announces-positive-3-month-data-from-phase-2-dawn-trial-of-agtc 2024-12-09T20:10:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/beacon-therapeutics-announces-positive-3-month-data-from-phase-2-dawn-trial-of-agtc 2024-12-09T20:10:11+00:00 weekly 0.7 https://trial.medpath.com/news/secura-bio-presented-new-data-from-its-phase-2-primo-trial-of-copiktra-r-duvelisib-in 2024-12-09T20:07:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/secura-bio-presented-new-data-from-its-phase-2-primo-trial-of-copiktra-r-duvelisib-in 2024-12-09T20:07:50+00:00 weekly 0.7 https://trial.medpath.com/news/corbus-pharma-launches-phase-1-trial-for-novel-cancer-immunotherapy-crb-601 2024-12-09T19:57:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corbus-pharma-launches-phase-1-trial-for-novel-cancer-immunotherapy-crb-601 2024-12-09T19:57:35+00:00 weekly 0.7 https://trial.medpath.com/news/affimed-reports-promising-phase-1-efficacy-and-safety-data-for-afm28-in-relapsed-refractory-acute-myeloid-leukemia 2024-12-09T19:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/affimed-reports-promising-phase-1-efficacy-and-safety-data-for-afm28-in-relapsed-refractory-acute-myeloid-leukemia 2024-12-09T19:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-enrolled-in-inspiremd-s-cguardians-ii-pivotal-study-vascular-news 2024-12-09T19:28:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-enrolled-in-inspiremd-s-cguardians-ii-pivotal-study-vascular-news 2024-12-09T19:28:58+00:00 weekly 0.7 https://trial.medpath.com/news/icer-potential-new-pain-medication-offers-small-savings-managed-healthcare-executive 2024-12-09T19:13:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/icer-potential-new-pain-medication-offers-small-savings-managed-healthcare-executive 2024-12-09T19:13:08+00:00 weekly 0.7 https://trial.medpath.com/news/deferasirox-achieves-transfusion-independence-in-mds-anemia-targeted-oncology 2024-12-09T19:04:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/deferasirox-achieves-transfusion-independence-in-mds-anemia-targeted-oncology 2024-12-09T19:04:09+00:00 weekly 0.7 https://trial.medpath.com/news/carta-healthcare-to-power-oncology-research-and-clinical-trials-with-acquisition-pr-newswire 2024-12-09T19:01:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/carta-healthcare-to-power-oncology-research-and-clinical-trials-with-acquisition-pr-newswire 2024-12-09T19:01:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-cancer-treatments 2024-12-09T18:56:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-cancer-treatments 2024-12-09T18:56:44+00:00 weekly 0.7 https://trial.medpath.com/news/adding-chemoradiation-in-perioperative-gastric-cancer-treatment-improves-pathologic 2024-12-09T18:47:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adding-chemoradiation-in-perioperative-gastric-cancer-treatment-improves-pathologic 2024-12-09T18:47:57+00:00 weekly 0.7 https://trial.medpath.com/news/endo-receives-u-s-fda-approval-of-manufacturing-facility-in-indore-india 2024-12-09T18:20:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/endo-receives-u-s-fda-approval-of-manufacturing-facility-in-indore-india 2024-12-09T18:20:58+00:00 weekly 0.7 https://trial.medpath.com/news/adenosine-antagonists-clinical-trial-pipeline-analysis-10-globenewswire 2024-12-09T18:05:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adenosine-antagonists-clinical-trial-pipeline-analysis-10-globenewswire 2024-12-09T18:05:53+00:00 weekly 0.7 https://trial.medpath.com/news/eu-decision-time-for-orphans-acoramidis-garadacimab-imetelstat-plus-10-other-products 2024-12-09T17:23:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-decision-time-for-orphans-acoramidis-garadacimab-imetelstat-plus-10-other-products 2024-12-09T17:23:33+00:00 weekly 0.7 https://trial.medpath.com/news/two-data-analyses-from-clinical-trials-show-epcoritamab-duobody-r-cd3xcd20 2024-12-09T17:07:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/two-data-analyses-from-clinical-trials-show-epcoritamab-duobody-r-cd3xcd20 2024-12-09T17:07:53+00:00 weekly 0.7 https://trial.medpath.com/news/tandem-non-cryopreserved-car-t-exhibits-favorable-activity-in-advanced-dlbcl-healio 2024-12-09T16:55:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tandem-non-cryopreserved-car-t-exhibits-favorable-activity-in-advanced-dlbcl-healio 2024-12-09T16:55:25+00:00 weekly 0.7 https://trial.medpath.com/news/filling-out-the-roadmap-for-faster-drug-approvals-inventum 2024-12-09T16:43:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/filling-out-the-roadmap-for-faster-drug-approvals-inventum 2024-12-09T16:43:28+00:00 weekly 0.7 https://trial.medpath.com/news/simple-hysterectomy-not-inferior-to-radical-hysterectomy-for-cervical-cancer-treatment 2024-12-09T16:25:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/simple-hysterectomy-not-inferior-to-radical-hysterectomy-for-cervical-cancer-treatment 2024-12-09T16:25:20+00:00 weekly 0.7 https://trial.medpath.com/news/four-therapies-that-may-treat-kennedy-s-disease-brain-and-life-magazine 2024-12-09T16:24:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/four-therapies-that-may-treat-kennedy-s-disease-brain-and-life-magazine 2024-12-09T16:24:03+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-ind-approval-to-base-therapeutics-base-edited-nk-cell-therapy-powered-by 2024-12-09T16:14:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-ind-approval-to-base-therapeutics-base-edited-nk-cell-therapy-powered-by 2024-12-09T16:14:59+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-lenvatinib-plus-gefitinib-in-lenvatinib-resistant-hepatocellular-carcinomas 2024-12-09T15:43:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-and-safety-of-lenvatinib-plus-gefitinib-in-lenvatinib-resistant-hepatocellular-carcinomas 2024-12-09T15:43:23+00:00 weekly 0.7 https://trial.medpath.com/news/interim-update-from-vico-therapeutics-on-their-cag-targeting-drug-vo659-hdbuzz 2024-12-09T15:41:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/interim-update-from-vico-therapeutics-on-their-cag-targeting-drug-vo659-hdbuzz 2024-12-09T15:41:17+00:00 weekly 0.7 https://trial.medpath.com/news/high-fiber-diets-may-reduce-risk-of-gvhd-after-bone-marrow-stem-cell-transplants 2024-12-09T15:40:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/high-fiber-diets-may-reduce-risk-of-gvhd-after-bone-marrow-stem-cell-transplants 2024-12-09T15:40:57+00:00 weekly 0.7 https://trial.medpath.com/news/stereotaxis-wins-approval-in-china-for-magnetic-ablation-catheter-massdevice 2024-12-09T15:35:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stereotaxis-wins-approval-in-china-for-magnetic-ablation-catheter-massdevice 2024-12-09T15:35:57+00:00 weekly 0.7 https://trial.medpath.com/news/tiakis-biotech-ag-reports-clinical-phase-ib-ii-trial-globenewswire 2024-12-09T15:01:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tiakis-biotech-ag-reports-clinical-phase-ib-ii-trial-globenewswire 2024-12-09T15:01:43+00:00 weekly 0.7 https://trial.medpath.com/news/modus-therapeutics-initiates-phase-ii-study-with-sevuparin-for-the-treatment-of-chronic-placera 2024-12-09T14:56:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/modus-therapeutics-initiates-phase-ii-study-with-sevuparin-for-the-treatment-of-chronic-placera 2024-12-09T14:56:52+00:00 weekly 0.7 https://trial.medpath.com/news/rural-pharmacists-face-mounting-challenges-expert-highlights-critical-workforce-and-safety-concerns 2024-12-09T14:50:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rural-pharmacists-face-mounting-challenges-expert-highlights-critical-workforce-and-safety-concerns 2024-12-09T14:50:43+00:00 weekly 0.7 https://trial.medpath.com/news/bionomics-publishes-the-positive-results-from-the-phase-2-attune-study-of-bnc210-biospace 2024-12-09T14:44:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bionomics-publishes-the-positive-results-from-the-phase-2-attune-study-of-bnc210-biospace 2024-12-09T14:44:29+00:00 weekly 0.7 https://trial.medpath.com/news/first-subject-dosed-in-initial-cohort-of-phase-2b-clinical-study-of-cyanvac-s-intranasal-biospace 2024-12-09T14:43:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-subject-dosed-in-initial-cohort-of-phase-2b-clinical-study-of-cyanvac-s-intranasal-biospace 2024-12-09T14:43:54+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-drug-succeeds-in-another-parkinson-s-trial-stat-news 2024-12-09T14:25:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-drug-succeeds-in-another-parkinson-s-trial-stat-news 2024-12-09T14:25:06+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-uptake-in-sickle-cell-stays-slow-despite-patient-interest-biopharma-dive 2024-12-09T14:20:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-therapy-uptake-in-sickle-cell-stays-slow-despite-patient-interest-biopharma-dive 2024-12-09T14:20:34+00:00 weekly 0.7 https://trial.medpath.com/news/early-signs-of-efficacy-for-a-novel-drug-and-a-new-predictive-tool-to-guide-patient-care 2024-12-09T14:19:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/early-signs-of-efficacy-for-a-novel-drug-and-a-new-predictive-tool-to-guide-patient-care 2024-12-09T14:19:27+00:00 weekly 0.7 https://trial.medpath.com/news/relmada-halts-depression-drug-trials-shifts-focus-to-psilocybin-program-amid-review 2024-12-09T14:13:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/relmada-halts-depression-drug-trials-shifts-focus-to-psilocybin-program-amid-review 2024-12-09T14:13:37+00:00 weekly 0.7 https://trial.medpath.com/news/woolsey-pharmaceuticals-reveals-breakthrough-findings-showing-spread-of-toxic-tdp-43 2024-12-09T14:02:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/woolsey-pharmaceuticals-reveals-breakthrough-findings-showing-spread-of-toxic-tdp-43 2024-12-09T14:02:49+00:00 weekly 0.7